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Abstract 
  Antibiotic resistance is emerging as a tremendous medical burden worldwide. The mode of action of 
antibiotics is based on killing or growth inhibition, thus leading to an inevitable selection of resistant strains. 
The predicament obliges human beings to explore novel therapeutic concepts. Quorum sensing (QS) 
communication system stringently regulates the bacterial pathogenicity without affecting viability making 
QS an ideal target for development of new anti-infectives being less prone to resistance (QS inhibitors, QSIs). 
For P. aeruginosa, we started to develop QSIs blocking its crucial QS receptor PqsR, and discovered the first 
PqsR antagonist I-20/II-1 by modification of the natural agonist HHQ. However, the antagonist suffered 
from ineffectiveness in P. aerugnosa due to an unexpected functional inversion mediated by a bacterial 
enzyme. Overcoming the undesired biotransformation resulted in the most potent anti-infective PqsR 
antagonist discovered so far (II-3) that  fully protects Galleria mellonella from P. aeruginosa infections at a 
low nanomolar concentration, thus providing the first proof-of-concept for PqsR as a therapeutic target. To 
improve the druglikeness, the compounds were further optimized, and a second promising compound III-16 
with enhanced solubility was identified. Overall, this work describes the discovery of inhibitors for a novel 
anti-infective target, a rational procedure for rescuing ineffective compounds, and a reasonable process to 
improve drug-like properties. This research may illuminate a promising avenue for combating antibiotic-
resistant P. aeruginosa infections. 
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Zusammenfassung 
  Antibiotikaresistenz stellt weltweit eine enorme medizinische Herausforderung dar. Da Antibiotika durch 
Abtötung der Krankheitserreger oder Hemmung des Zellwachstums wirken, kommt es unvermeidlich zur 
Selektion von resistenten Bakterienstämmen. Deswegen ist die Forschung gezwungen, neue therapeutische 
Konzepte zu entwickeln. Das Quorum Sensing (QS) Kommunikationssystem reguliert die Pathogenität der 
Bakterien ohne ihre Lebensfähigkeit zu beeinflussen. Deshalb wird QS als ein ideales Target angesehen, um 
neue anti-infektive Wirkstoffe (QS Inhibitoren, QSIs) zu entwickeln, die eine deutlich geringere 
Resistenzbildungsrate besitzen sollten. Für P. aeruginosa haben wir begonnen QSIs gegen den wichtigen QS 
Rezeptor PqsR zu entwickeln. Die ersten PqsR Antagonisten (z.B. I-20/II-1) wurden durch Modifikation des 
natürlichen Agonisten HHQ erhalten. Der aktivste Antagonist war in P. aeruginosa wenig wirksam,was auf 
eine unerwartete Umkehr der Funktionalität der Substanz zurückgeführt werden konnte. Schutz vor der 
ungewollten Biotransformation durch chemische Modifikation führte zu dem aktivsten anti-infektiven 
Wirkstoff (II-3) innerhalb dieser Arbeit. Bei einer Konzentration von nur 22 nM konnte II-3 Galleria 
Mellonella vollständig vor P. aeruginosa Infektion schützen. Somit haben wir das erste Proof-of-Concept für 
die Relevanz von PqsR als therapeutisches Target geliefert. Zur Verbesserung der Druglikeness wurden die 
Verbindungen weiter optimiert. Dabei wurde eine weitere vielversprechende Verbindung III-16 mit 
verbesserter Löslichkeit identifiziert. Zusammenfassend beschreibt die vorliegende Arbeit die Identifizierung 
von Inhibitoren eines neuen anti-infektiven Targets, die Rettung inaktiver Substanzen durch eine rationale 
Strategie, sowie ein Verfahren zur Verbesserung der physicochemischen Wirkstoffeigenschaften. Sie zeigt 
einen möglichen Weg auf, um zukünftig Antibiotika-resistente Infektionen mit P. aeruginosa zu bekämpfen. 
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1 Introduction 
Nowadays, it is well recognized that bacteria do not live as a loose community but organize their 
behaviors via cell-to-cell communication systems and act as a multicellular organism. Such well 
coordinated group behaviors are usually associated with pathogenicity (e.g. production of virulence 
factors, formation of biofilm), however, normally not involved in bacterial viability. Along with the 
understanding of bacterial communication, a novel anti-infective strategy is brought to light, which 
selectively attenuates bacterial pathogenicity without affecting the growth by disrupting cell-to-cell 
communication. Such a strategy would in all probability bring us the dawn of overcoming the rising 
problem of antibiotic resistance during the long-lasting war between human beings and pathogenic 
bacteria. 
 
1.1 Pseudomonas aeruginosa 
  Pseudomonas aeruginosa is a common important Gram-negative bacterium (Figure 1) first 
isolated in 1882 by the French pharmacist and bacteriologist Carle Gessard from wound of soldiers 
whose bandages had a blue and green color (Gessard, 1984). It possesses a notable large and diverse 
genome of 5–7 Mb encoding circa 6000 open reading frames (ORFs) (Stover et al., 2000). The high 
genetic and metabolic versatility enables P. aeruginosa to adapt most natural and artificial 
environments throughout the world from soil, water, tissues of plants and animals, medical 
equipments, even to International Space Station (ISS) (Kim et al., 2013). 
 
Figure 1. Scanning electron micrograph (SEM) of P. aeruginosa.  
(adopted from http://phil.cdc.gov/phil/details.asp?pid=10043) 
 
  As an opportunistic human pathogen P. aeruginosa is able to colonize in burns, wound, blood, 
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gastrointestinal, pulmonary and urinary tracts, and is a leading cause of life-threatening nosocomial 
infections. It preferentially infects immuno-compromised individuals and cystic fibrosis (CF) 
patients, and is the main responsible factor for chronic lung infections (Koch and Hoiby, 1993) as 
well as the mortality of CF patients (Govan and Deretic, 1996). 
The eradication of P. aeruginosa is a great medical challenge because it is intrinsically resistant 
to antibiotics or disinfectants (Strateva and Yordanov, 2009). Besides, this microorganism is able to 
produce an arsenal of virulence factors as well as establish microcolonies encased with 
exopolysaccharides forming a biofilm community. Virulence factors and biofilm help the bacterial 
cells to effectively counterwork the human immune response and dramatically decrease the 
susceptibility to antibiotics (Costerton et al., 1999). 
 
1.2 Quorum Sensing (QS) and QS-regulated Pathogenicity/ Virulence 
of P. aeruginosa 
 
1.2.1 Quorum Sensing 
  Quorum sensing (QS) is a cell-to-cell communication system first discovered in the 
bioluminescent bacterium Vibrio fischeri (Nealson et al., 1970). It allows bacteria to determine their 
local population, make cell density-dependent collective decisions thereby coordinating the whole 
bacterial community to behavior like a multicellular organism (Figure 2). Notably, such well 
coordinated group behaviors are normally not involved in bacterial viability (Galloway et al., 2012; 
LaSarre and Federle, 2013) but always connected to pathogenicity/virulence, including the 
expression of virulence factors, the formation of biofilm, swarming, swimming as well as twitching, 
which facilitate the invasion into the hosts, counteract host immune system as well as promote 
resistance/tolerance towards conventional antibiotics (Miller and Bassler, 2001). 
  A typical QS system consists of three components: a signal molecule (termed autoinducer or AI), 
a receptor/transcriptional regulator and a synthase producing AI. AI is able to specifically activate 
the receptor thereby initiating the transcription of certain genes including those for AI biosynthesis 
(gene encoding the synthase), which enables a positive autoinducing loop. However, at a low 
population the AI secreted into the surrounding medium is strongly diluted due to the diffusion, thus, 
the activation of the receptor is only at a basal level. As the cell density increases, the AI reaches a 
threshold concentration leading to a full activation of the receptor and up-regulation of target genes, 
most of which, as mentioned above, are related to the bacterial pathogenicity (Figure 2) (Miller and 
Bassler, 2001). 
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Figure 2. Pathogen determines cell density and coordinates gene expression for infections via 
QS communication. 
 
  P. aeruginosa employs three main QS systems, denoted las (Gambello and Iglewski, 1991; 
Passador et al., 1993), rhl (Ochsner et al., 1994; Ochsner and Reiser, 1995) and pqs (Pesci et al., 
1999). All the networks are hierarchically interconnected: las controls the other two systems (Pesci 
et al., 1997; Wade et al., 2005), and is therefore regarded as the master regulator; pqs positively 
regulates the rhl signaling (McKnight et al., 2000), while rhl in turn puts a negative feedback upon 
pqs (Figure 3) (McGrath et al., 2004; Wade et al., 2005). Although las is generally to be considered 
to sit on the top of the QS hierarchy of P. aeruginosa, it is worth to note that the subordinate 
systems, rhl and pqs, can still be activated in the absence of las under certain conditions (Dekimpe 
and Deziel, 2009; Diggle et al., 2003; Lee et al., 2013). 
For the las QS the synthase LasI produces the AI N-3-oxododecanoyl-L- homoserine lactone 
(3-oxo-C12-HSL), which activates the receptor LasR. Similarly, RhlI produces 
N-butanoyl-L-homoserine lactone (C4-HSL), which stimulates RhlR. While both 
homoserine-mediated QS systems are broadly applied by various bacteria, the recently discovered 
species-specific pqs QS only occurs in Pseudomonas (Pesci et al., 1999), and is receiving increasing 
attention. The Pseudomonas Quinolone Signal (PQS) and to a lesser extent its precursor 
2-heptyl-4-hydroxyquinoline (HHQ), two most predominant members of the 
2-alkyl-4-hydroxyquinoline (HAQ) family (Deziel et al., 2004) function as AIs of the pqs system, 
and activate their cognate receptor PqsR (Cao et al., 2001; Xiao et al., 2006), a LysR-type 
transcriptional regulator (Maddocks and Oyston, 2008) that drives the coordinated expression of 
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nearly 200 genes (Figure 3). Many of these genes are related to virulence factors, such as phzA1-G1, 
which is involved in the biosynthesis of pyocyanin, hcnAB, which is responsible for production of 
hydrogen cyanide, lasB, which encodes elastase B and lecA, which codes for Lectin A (Cao et al., 
2001; Deziel et al., 2005). The pqs QS also indirectly promotes the production of rhamnolipids via 
activating the rhl system as mentioned before. Besides virulence factors, biofilm formation is also 
regulated by the pqs system (Diggle et al., 2003). Moreover, other QS regulated activities, for 
instance membrane vesicles formation (Mashburn-Warren et al., 2009; Mashburn-Warren et al., 
2008), are under the control of pqs signaling. Furthermore, PqsR activates pqsABCD located in the 
pqs operon to express the synthases, which conduct the biosynthesis of the AI HHQ, which is 
further converted to PQS by the LasR-regulated monooxygenase PqsH (Deziel et al., 2004; 
Gallagher et al., 2002; Schertzer et al., 2010). Thus, a positive feedback is triggered by activation of 
PqsR by either PQS or HHQ (McGrath et al., 2004), which allows an initial rapid increase of 
extracellular PQS levels during an exponential growth phase. 
 
 
Figure 3. Three intertwined QS systems in P. aeruginosa. 
 
1.2.2 Virulence Factors 
  Virulence factors are molecules or cell structures expressed by pathogenic bacteria contributing 
to the virulence/pathogenicity such as destructive enzymes, toxins, siderophores, pili and flagella. 
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The virulence factors empower the bacteria to invade the host, escape from host immune 
surveillance, repress the host immune response, as well as decrease the susceptibility towards 
antibiotics (Lyczak et al., 2000). The virulence factors play undoubtedly a critical role for the 
infections, however, they are normally not involved in bacterial growth (Galloway et al., 2012; 
LaSarre and Federle, 2013). In this section elastase B, rhamnolipids and pyocyanin are chosen as 
representative virulence factors of P. aeruginosa, which are directly or indirectly controlled by pqs 
QS. 
 
1.2.2.1 Elastase B 
  Elastase B, also termed LasB protease, pseudomonas elastase (PE) or pseudolysin, is a 33 kDa 
elastolystic metalloprotease from the thermolysin family (Kessler et al., 1998; Morihara, 1995) 
encoded by the lasB gene of P. aeruginosa. The activation of lasB is positively controlled by pqs 
QS, and exogenous PQS strongly induces expression of elastase B even in the las mutant 
(McKnight et al., 2000). This destructive enzyme is able to destroy host tissues via specific 
cleavage of the structural proteins such as type III and IV collagens (Heck et al., 1986), which are 
common components of the extracellular matrix widely existing in dermis, lung, blood vessel walls, 
liver and spleen (Miller and Gay, 1982). Elastase B damages tight junction-associated proteins 
ZO-1 and ZO-2 thereby breaking down the epithelial barriers (Azghani, 1996; Azghani et al., 1990; 
Azghani et al., 1993). Moreover, this protease also functions as a powerful weapon towards host 
innate and adaptive immune systems, since it degrades a battery of cytokines (e.g. INF-γ, IL-2 and 
IL-8), chemokines, immunoglobulins (e.g. IgA and IgG), human airway lysozymes (Jacquot et al., 
1985), antimicrobial peptides (AMPs) as well as phagocytosis-related surfactant proteins e.g. SP-A 
Kuang (Kuang et al., 2011). Overall, Elastase B supports the P. aeruginosa infections in a variety of 
ways, and therefore is regarded as an important contributor to pathogenicity. 
 
1.2.2.2 Rhamnolipids 
  Rhamnolipids are a class of glycolipids produced by P. aeruginosa including monorhamnolipid 
and dirhamnolipid (Chart 1). Three enzymes RhlA, RhlB and RhlC, all of which are under control 
of pqs and rhl QS (Deziel et al., 2005; Ochsner et al., 1994; Ochsner and Reiser, 1995; Rahim et al., 
2001), are required for the biosynthesis of rhamnolipids. 
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Chart 1. Structures of rhamnolipids. 
 
  Although these heat-stable glycolipids are well known for their properties as biosurfactants, 
multiple biological functions have been discovered. First, rhamnolipids guarantee a trouble-free QS 
communication. The AI of pqs QS, PQS, shows a poor solubility due to the high lipophilicity 
making a great problem for signal transmission for P. aeruginosa. Besides packing PQS into 
membrane vesicles (MVs) to assist the delivery (Mashburn and Whiteley, 2005), the bacteria also 
use rhamnolipids to enhance the solubility of PQS likely via forming micelles (Calfee et al., 2005). 
Second, rhamnolipids act as wetting agents to reduce surface tension and correspondingly enhance 
bacterial translocation abilities in the medium e.g. swarming and twitching (Glick et al., 2010). Due 
to the massive influence on bacterial motility the surfactants play a crucial role for determining and 
maintaining biofilm architecture. Rhamnolipids are responsible for keeping the fluid channels 
around the biofilm open possibly by preventing planktonic cells from attaching to the formed 
biofilm. This is supported by the result that rhlA mutant, which is not able to produce rhamnolipids, 
is unable to sustain the water channels around the biofilm and forms a thick and flat biofilm (Davey 
et al., 2003). Third, rhamnolipids function as toxins to host cells. In addition to rupturing 
erythrocytes (hemolysis) (Johnson and Boese-Marrazzo, 1980), this virulence determinant is 
detrimental to immunocytes, particularly, the polymorphonuclear leukocytes (PMNs), which are 
directly induced to necrosis (Jensen et al., 2007). Usually, rhamnolipids form an anti-PMNs shield 
outside of the biofilm in vivo and collapse the attack of PMNs besieging the P. aeruginosa 
aggregate. The subsequent necrotic lysis of the immunological cells not only elevates the 
inflammation levels to recruit more PMNs to be victims of rhamnolipids killing but also supplies 
more extracellular DNA (eDNA, a component of biofilm, also see below, “1.2.3 biofilm”) to 
strengthen the biofilm (Alhede et al., 2014). All the evidences underline the crucial role of 
rhamnolipids in the infectious process. 
 
1.2.2.3 Pyocyanin 
  Pyocyanin is a redox-active pigment possessing a phenazine core (Chart 2). Its biosynthesis is 
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conducted by synthases PhzA1-G1, PhzM and PhzS. There is an intimate connexion with pqs QS. 
On one hand, HHQ/PQS-deficient mutants (pqsA and pqsR mutants) are unable to produce 
pyocyanin (Cao et al., 2001; Deziel et al., 2004); on the other hand, pyocyanin formation is also 
controlled in a HHQ/PQS-independent manner by the action of PqsE, which is co-regulated in the 
pqs operon (pqsABCDE), and is able to restore pyocyanin levels in pqsA or pqsR mutants (Farrow 
et al., 2008; Rampioni et al., 2010).  
 
 
Chart 2. Structures of pyocyanin. 
 
  As a multifunctional virulence factor pyocyanin is of great significance for P. aeruginosa. First, 
due to its redox properties pyocyanin functions as an electron transporter that accepts and transfers 
electrons generated from bacterial respiration chain to electron acceptors distant from the colonies 
(e.g. an air-water interface), thus, enable the aerobic respiration of P. aeruginosa even under 
oxygen-limited conditions (Rada and Leto, 2013). Second, this compound displays antibiotic 
activities towards protozoa, fungi and bacteria, especially Gram-positive bacteria, therefore helping 
its producer organism to gain advantages over other competitors in the environment (Baron and 
Rowe, 1981). Third, the interaction between pyocyanin and molecular oxygen affords reactive 
oxygen species (ROS) e.g. H2O2, which induces a cell lysis of P. aeruginosa and subsequently 
promotes the release of eDNA (Das and Manefield, 2012). This result implies that the virulence 
determinant may indirectly contribute to biofilm formation (Das et al., 2013). Fourth, pyocyanin 
causes massive cell dysfunction, injury and death of hosts. Most of these activities are attributed to 
the disruption of redox homeostasis, in other words, exposure of host cells to oxidative stress, by 
means of depleting intracellular pools of NAD(P)H and glutathione (GSH), generating superoxide 
as well as downstream ROS (Muller, 2002; O'Malley et al., 2004). Particularly for mammalian cells 
pyocyanin has a variety of biological effects: it elicits mucin overproduction, and diminishes the 
ciliary beat frequency (CBF) of nasal ciliated epithelium cells preventing the host from wiping out 
the pathogens (Wilson et al., 1988); it decreases mitochondrial aconitase activity and membrane 
potential, represses the cellular respiration and depletes intracellular ATP levels (O'Malley et al., 
2003a); it inactivates vacuolar ATPase (V-ATPase), and interrupts non-mitochondrial ATP 
consumption and generation as well as V-ATPase-regulated physiological processes e.g. 
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receptor-mediated endocytosis and altered localization of cystic fibrosis transmembrane 
conductance regulator (Lau et al., 2004); it also impairs the cellular catalase activity via both 
transcriptional regulation and direct inactivation of the enzyme depriving the ability of the cells to 
break down the tissue-damaging H2O2 (O'Malley et al., 2003b). Besides, pyocyanin is able to block 
the dual oxidase-thiocyanate-lactoperoxidase (Duox/SCN-/LPO) system hampering the production 
of microbicidal oxidant hypothiocyanite (Rada et al., 2008). Moreover, pyocyanin modulates host 
immune response by induction of a series of cytokines, such as TNF-a, IL-1β, granulocyte 
colony-stimulating factor (GCSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), 
IL-6, IL-11, IL-19, IL-20, IL-23 and IL-24, many of which are involved in the inflammatory 
process (Rada et al., 2011). The multiple biological functions, especially the ability to interact with 
hosts emphasize pyocyanin as a key virulence factor of P. aeruginosa. 
 
1.2.3 Biofilm 
  Under appropriate conditions, planktonically grown P .aeruginosa can switch from the nomadic 
existence to a biofilm lifestyle. A biofilm is defined as a structured community of aggregated 
bacterial cells embedded into self-produced extracellular polymeric substances (EPS) composed of 
polysaccharides, eDNA and proteins (Costerton et al., 1999; Costerton et al., 2003). 
 
 
Figure 3. SEM image of P. aeruginosa biofilm. 
(modified from http://eyemicrobiology.upmc.com/PhotoGallery.htm. The author expresses his 
thanks to the Charles T. Campbell Laboratory and Dr. R. M. Q. Shanks for this figure) 
 
QS is closely connected with such a process (Irie and Parsek, 2008), as the communication 
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systems control an array of factors that structure biofilm formation, such as rhamnolipids, as 
mentioned before, which actively maintain open channels that allow the distribution of nutrients 
and oxygen in the community (Davey et al., 2003), lectins A and B (Winzer et al., 2000), which 
may contribute to the adhesion of bacteria to the corresponding host tissue, and eDNA resulted from 
bacterial autolysis provoked either by pyocyanin (Das and Manefield, 2012) or directly by pqs QS 
(D'Argenio et al., 2002), which is a main component of the extracellular matrix. Biofilm not only 
provides the bacteria a shelter for hiding but also, more importantly, protect the pathogen from a 
broad spectrum of environmental challenges, particularly antibiotics and host immune system 
(Hall-Stoodley et al., 2004). Biofilm dramatically increases bacterial tolerance towards traditional 
antimicrobial agents via diverse mechanisms: first, it serves as a physical diffusion barrier hindering 
certain antibiotics to penetrate into the full depth of the biofilm; second, special constituents of EPS 
are able to actively neutralize antibiotics, e.g. the negatively charged eDNA can either directly bind 
drugs with opposite charges like aminoglycosides, thus impeding the access to the sites of action 
(Purdy Drew et al., 2009; Ramphal et al., 1988), or indirectly induce pmr genes to counteract AMPs 
(Mulcahy et al., 2008); third, due to nutrient limitation inside the biofilm, the regular bacterial cells 
exist in a low-growing or starve state having a reduced metabolism rate, and this physiological 
status leads to diminished sensitivity towards antibiotics targeting active cell process (Costerton et 
al., 1999); fourth, in addition to the regular cells, there is a small subpopulation of spontaneously 
dormant and non-dividing variants termed persister cells living in the community, which are much 
more tolerant towards antimicrobials than other cells (Lewis, 2010). The protective effects of 
biofilm against host immune system are generally based on physical shielding, induction of necrosis 
of immunological cells as well as cleavage of immune-related proteins as mentioned above. 
 
1.3 PqsR Antagonists as QS Inhibitors (QSIs) for Anti- virulence 
Therapy against P. aeruginosa Infections 
 
1.3.1 Anti-virulence Therapy via Quorum Sensing Inhibition 
  Nowadays, human beings are confronted with an alarming situation in view of the lack of 
effective therapies against antibiotic-resistant bacterial infections (Arias and Murray, 2009). The 
predicament is attributed to the mode of action of marketed antibiotics, which is based on 
interference with bacterial growth (via e.g. targeting cell-wall biosynthesis, inhibiting protein 
production, or disrupting DNA replication), which results in an inevitable selection of resistant 
strains (Levy and Marshall, 2004). The emergence of bacterial resistance urgently requires the 
development of novel anti-infective strategies, however, unfortunately, the discovery of novel 
anti-infectives that are less prone to resistance is challenging, and the interest of the pharmaceutical 
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industry to develop new antibiotics is decreasing (Lewis, 2012). 
The anti-virulence therapy is a promising strategy to overcome the growing and challenging 
resistance problem by means of targeting non-vital cell functions that are associated with the 
bacterial pathogenicity. This novel therapeutic concept has decided advantages over conventional 
antibiotics-treatment, because the selective intervention into the pathogenic mechanisms without 
affecting on bacterial viability reduces natural election pressure and therefore delays or avoids the 
development of resistance (Cegelski et al., 2008; Galloway et al., 2012; Rasko et al., 2008). 
Since QS regulates the expression of a large set of pathogenicity-associated genes, corruption of 
the cell-to-cell communication system by QS inhibitors (QSIs) is an ideal approach for an 
anti-virulence therapy to disarm rather than kill the pathogens. Basically, three key nodes of the 
network can be targeted by QSIs: 1) blockade of signal molecule production, e.g. via inhibiting AI 
synthases; 2) inactivation of signal molecules, via chemical or enzymatic destruction of AIs; 3) 
interference with signal receptors via antagonizing endogenous agonists or destructing the receptor 
(Rasmussen and Givskov, 2006a, b). 
 
1.3.2 PqsR as an Eligible Target for QSIs 
  P. aeruginosa causes severe and fatal infections and possesses significant intrinsic resistance 
towards a wide range of conventional antimicrobials including β-lactams, fluoroquinolones, 
tetracycline, and chloramphenicol (Strateva and Yordanov, 2009). Search for a novel and effective 
approach to cure the obstinate P. aeruginosa infections, anti-virulence therapy via QSIs has been 
absorbing great attention of researchers worldwide. 
QSIs interfering with HSL-based signal pathways (las and rhl systems) have been investigated. 
The majority of these anti-las or anti-rhl QSIs are natural product-derived halogenated furanone 
compounds (Hentzer et al., 2003) and HSL analogs (Galloway et al., 2011). However, such QSIs 
suffered from either cytotoxicity towards mammalian cells (Yang et al., 2014) or low activity of 
repressing the production of virulence factors, and none of them has reached clinical studies to date. 
  While other research groups are concentrating on compounds targeting las or rhl QS, we focus on 
the P. aeruginosa specific pqs QS, and regard the receptor PqsR as a highly attractive target to 
develop QSIs (PqsR antagonists) for the following reasons: 1) as mentioned above, pqs QS plays a 
critical role for the pathogenicity, thus, we believe that the blockage of PqsR should attenuate the 
pqs-dependent virulence. This concept has been supported by the fact that the pqsR mutant strain 
displays a reduced mortality rate in mice (Xiao et al., 2006). Additionally, the mutation of 
pqs-controlled virulence genes results in decreased pathogenicity in plants, nematodes and insects 
(Jander et al., 2000; Mahajan-Miklos et al., 1999). Moreover, based on the fact that PQS is 
produced in high amounts in the sputum of the CF patients (Collier et al., 2002), it is assumed that 
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blocking the pqs QS system should make the P. aeruginosa lung infection in CF patients better 
treatable. 2) Whereas HSL-mediated QS is widespread among Gram-negative bacteria, we 
speculate that species-selective targeting of specific regulatory pqs QS might help to minimize 
adverse effects on beneficial bacterial consortia present in the host that are observed with 
broad-spectrum antibiotics. 3) Considering that the results obtained with inhibitors of AI synthases 
are less than satisfactory (PqsA and PqsD inhibitors require high concentrations to achieve desirable 
effects) (Lesic et al., 2007; Storz et al., 2012), we suspect that antagonizing endogenous ligands at 
the signal receptor should more directly and efficiently impact the QS circuit than blocking of the 
signal synthases. To the best of our knowledge, there were no such antagonists reported until we 
started this project. During the cause of the project we discovered the first QSIs targeting PqsR in 
2012. 
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2 Work Strategy 
 
2.1 Design of PqsR Antagonists 
  To the best of our knowledge, there is no appropriate crystal structure of PqsR with satisfactory 
resolution available for protein structure-based drug design to date, and no antagonist of this 
receptor had been reported before we started this project. The natural ligands, PQS and HHQ are all 
agonists. Nevertheless, we used them for the design of potential antagonists (ligand-based 
approach), since it has been known for a long time that antagonists can be obtained by structural 
modification of agonists (Hartmann et al., 1980). 
Although PQS is the most potent natural ligand, we used the less potent HHQ (Xiao et al., 2006) 
as a starting point for the following reasons: 1) the 3-hydroxy group of PQS has been proven to be 
responsible for interaction with lipid A of outer membrane lipopolysaccharides (Mashburn-Warren 
et al., 2008). Thus, HHQ lacking this group should exhibit a lower tendency to membrane 
association. 2) HHQ does not display iron chelating (Bredenbruch et al., 2006; Diggle et al., 2007) 
or pro-oxidant properties in contrast to PQS (Haussler and Becker, 2008). Therefore modification of 
HHQ should avoid these unwanted interactions. Initially, we modified the stereo-electronic 
configuration of HHQ by changing the length of the alkyl side chain and by introducing 
electron-donating (EDG) and withdrawing groups (EWG) into the benzene moiety of the quinolone 
structure. In the next step, to further optimize the active compounds regarding stability and water 
solubility, the 3-position of HHQ was substituted by diverse functional groups, and an oxygen atom 
was inserted into the alkyl side chain. 
 
2.2 Biological Evaluation of Synthesized Compounds 
  The functionality of the prepared compounds towards PqsR was initially determined in a 
β-galactosidase reporter gene assay established in E. coli. Strong antagonists were then investigated 
in a second reporter gene assay constructed in P. aeruginosa. Next, the potent compounds were 
assayed using P. aeruginosa wild type PA14 for their biological effects on the production of AIs as 
well as the virulence factor pyocyanin. Finally, the in vivo anti-virulence potency of the most 
promising compound was evaluated in nematode and insect infection models. Besides, water 
solubility and iron-chelating properties were detected using standard HPLC and CAS methods, 
respectively. 
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3 Results and Discussions 
 
3.1 Paper I: Discovery of Antagonists of PqsR, a Key Player in 
2-Alkyl-4-quinolone-Dependent Quorum Sensing in Pseudomonas 
aeruginosa 
 
This paper has been published in Chemistry & Biology 2012, 19, 381–390.  
Reprinted with permission from Elsevier. 
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3.2 Paper II: Overcoming the Unexpected Functional Inversion of a 
PqsR Antagonist in Pseudomonas aeruginosa: an in vivo Potent 
Antivirulence Agent Targeting pqs Quorum Sensing 
 
This paper has been published in Angewandte Chemie International Edition 2014, 53, 1109–1112. 
Reprinted with permission from John Wiley and Sons. 
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3.3 Paper III: Optimization of Anti-virulence PqsR Antagonists 
Regarding Aqueous Solubility and Biological Properties Resulting in 
New Insights in Structure-activity Relationships 
 
This paper has been published in European Journal of Medicinal Chemistry 2014, 79, 173–183. 
Reprinted with permission from Elsevier. Copyright © 2014 Elsevier Masson SAS. All rights 
reserved. 
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3.4 Evaluation of the Inhibitory Effects on Biofilm Formation 
  Recently, it was demostrated that blocking PqsR via small molecules indeed attenuates the 
biofilm development of P. aeruginosa (Ilangovan et al., 2013), which encouraged us to investigate 
the anti-biofilm activity for the most promising antagonist I-20/II-1. However, the results obtained 
from two distinct assays are ambiguous: in the crystal violet staining assay (O'Toole et al., 1999) a 
10%-25% reduction of biofilm formation was observed in the presence of the compound at a 
concentration of 15 µM; in contrast, in the viability staining assay combined with automated 
confocal laser scanning microscopy (CLSM) (Musken et al., 2010) there was no inhibition recorded. 
In the future, further studies will be conducted to clarify the inhibitory effects of the PqsR 
antagonists on P. aeruginosa biofilm. 
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4 Summary, Conclusion and Outlook 
 
4.1 Summary and Conclusion 
PqsR is the receptor of the P. aeruginosa-specific pqs QS circuit, and functions as a critical 
regulator that fine-tunes the expression of a large set of pathogenicity-associated genes, most of 
which are involved in the production of virulence factors and biofilm formation. We regard this 
virulence regulator as an attractive drug target, and discovered anti-virulence compounds blocking 
PqsR (PqsR antagonists) to effectively diminish bacterial pathogenicity without provoking 
resistance. 
 
4.1.1 Discovery of the First PqsR Antagonists 
  Because of the lack of an appropriate crystal structure of PqsR, we have applied a ligand-based 
design strategy to explore PqsR antagonists via structural modification of the natural 
ligands/agonists of the receptor, and subsequently identified PqsR antagonists by means of 
introducing strong EWGs like CN, CF3 or NO2 into the 6-position of HHQ. All of the antagonists 
I-18, I-19 and I-20/II-1 exhibited high activity towards PqsR with IC50s in low nanomolar range in 
the E coli.-based reporter gene assay. This work led to the discovery of the first PqsR antagonists. 
 
4.1.2 Identification of the most Potent PqsR Antagonist and the First Proof-of-concept for 
PqsR-targeting Therapy 
  Despite high activity displayed in the E coli.-based reporter gene assay, the first PqsR antagonist 
I-20/II-1 is unable to efficiently repress the pqs QS activity as well as the production of virulence 
factor pyocynin in P. aeruginosa. A thorough investigation of this phenomenon revealed that the 
ineffectiveness of I-20/II-1 in the pathogen is attributed to an unexpected functional inversion 
mediated by the bacterial enzyme PqsH that converts the strong antagonist into a potent agonist II-2. 
Consequently, we utilized medicinal-chemistry strategies to overcome the problem and reshaped the 
antagonist I-20/II-1 yielding compound II-3, which fully protects Galleria mellonella larvae from 
lethal P. aeruginosa infections at a low nanomolar concentration (22 nM). To the best of our 
knowledge, compound II-3 is the most active anti-virulence compound interfering with PqsR 
reported to date (Ilangovan et al., 2013; Klein et al., 2012; Zender et al., 2013). This work provided 
the first proof-of-concept for PqsR as a target for anti-virulence therapy. 
 
4.1.3 Development of PqsR Antagonists with Improved Physicochemical Properties 
  Our PqsR antagonists turned out to be promising anti-virulence agents, however, these 
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compounds suffered from poor aqueous solubility that hinders them to be proper drug candidates. 
Thus, the antagonists were structurally modified by means of introducing polar or ionizable groups 
into the quinolone core or the alkyl side chain to improve their solubility. SARs as well as SPRs 
thus obtained were systematically studied. In this work new insights into ligand-receptor 
interactions were provided and a novel potent compound, III-16, with improved solubility was 
developed. 
 
4.2 Outlook 
  In the next step the highly potent PqsR antagonists will be proceeded in mouse infection models 
e.g. tumor model, lung infection model and burn wound model, to investigate the in vivo 
anti-virulence efficacy in mammalian species. 
  Recently, the cocrystal structure of PqsR with ligands was reported by another group (Ilangovan 
et al., 2013), however, the resolution was poor. In cooperation with other group (Xu et al., 2012) we 
are also aiming at getting a high quality crystal structure of PqsR, which will assist us in elucidating 
the mechanism of action (MOA) of receptor activation/inactivation. This may in turn facilitate the 
antagonist design and optimization in the future. 
  Meanwhile, the existing PqsR antagonists are going to be further modified regarding activity as 
well as physicochemical properties. Noteworthy, the poor water solubility of this compound class 
can be a problem obstructing the way to drug candidates for a systemic administration (e.g. oral 
administration). To solve this problem, we have planned to replace the left benzene ring as well as 
groups at 1- or 3-position with other more polar or ionizable counterparts. Moreover, we are also 
investigating diverse delivery systems e.g. packing the highly lipophilic antagonists into 
nanoparticles or liposomes. Although further optimization is needed for the systemic application, 
we suggest that these compounds should be readily applicable for a topical treatment that is less 
affected by solubility. Application of the compounds in a form of aerosol to cure lung infections and 
administration as creme to deal with skin infections are promising options to achieve a local 
therapeutic effect. 
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6 Appendix 
 
6.1 Supplemental Information for Paper I 
 
Table S1. Agonistic and Antagonistic Activities of PQS Analogues 
      
      
PqsR stimulation 
induced by 50 nM test 
compd. compared to 50 
nM PQS (= 1.00) 
Inhibition of PqsR 
stimulation induced by 
50 nM PQS in the 
presence of 50 nM test 
compd. (full inhibition 
= 1.00 ) 
 
 
 
 
Compd. 
 
 
 
R 
 
 
 
R” 
    
 
 
Variation of 
side chain 
31 n-C5H11 H 0.12 0.08 
32 n-C6H13 H 0.54*
 
0.04 
33 n-C7H15 H 1.00* - 
 34 n-C8H17 H 0.91* n.d.
a
 
 35 n-C9H19 H 0.81* n.d. 
Introduction of 
substituents in 
the 
carbocyclic 
ring 
36 n-C7H15 6-OCH3 0.04 
 
0.17 
37 n-C7H15 7-OCH3 1.06* 
 
n.d. 
38 n-C7H15 8-F 0.12 
 
-0.07 
39 n-C7H15 6-F 1.07* 
 
n.d. 
40 n-C7H15 6-CH3 0.35 
 
-0.04 
41 n-C7H15 6-I 0.26* 
 
0.03 
 42 n-C7H15 6,7-benzo 0.08 
 
-0.07 
β-Galactosidase reporter gene assay was performed in E. coli transformed with the plasmid pEAL08-2 encoding PqsR and 
the reporter gene lacZ controlled by the pqsA promoter. For the agonist test, the compounds were measured at 50 nM and 
5 µM (data not shown); for the antagonist test, the compounds were measured at 50 nM and 5 µM (data not shown) in the 
presence of 50 nM PQS. Mean value of at least two independent experiments with n=4, standard deviation less than 25%. 
Significance: For the agonist test, induction compared to the basal value; for the antagonist test, decrease of the 
PQS-induced induction. * p < 0.05. 
a
 n.d. not determined 
 
 
Table S2. Determination of Water Solubility 
Compd. Water solubility [μM] 
23 >300 
25 200-300 
27 5-15 
19 <5 
Aqueous solutions (containing 5% DMSO) of the test compounds were prepared with final theoretical concentrations of 
5, 15, 50, 100, 200 and 300 μM. The solution clarity was examined. 
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Table S3. Determination of Antibacterial Activity in E. coli tolC 
 
 
Compd.
a
 
Mass loaded 
on the paper 
disc  [µg] 
Diameter 
of inhibition 
[cm] 
 
Chloramphenicol 
 5 1.9 
 10 2.0 
 15 2.2 
 20 2.3 
2
b
  25 1.3 
3  25 1.1 
4  25 1.2 
5  25 1.2 
6  25 1.1 
11  25 1.2 
Antibacterial activity of compounds was determined in E. coli tolC applying a filter disc technique. Chloramphenicol 
was used as the positive control. Mean value of at least two independent experiments, standard deviation less than 25%. 
a
 All other compounds did not exhibit antibacterial properties. 
b
 Standard deviation 28%. 
 
 
Figure S1. Binding Affinity for Compound 18  
a) Overlay of sensorgrams for compound 18 binding to H6SUMO-PqsR
C87
 measured at 12 °C. The data read-out line is 
indicated by the dashed line. b) Fitting of compound 18 equilibrium response data from the His6SUMO-PqsR
C87
 surface 
to a steady state 1:1 model to calculate Kd ((I) 54 nM, (II) 60 nM; mean 57 nM). c) Fiting of compound 18 kinetic data 
to a simple 1:1 interaction model including mass transport component (orange lines) to calculate Kd ((I) 45 nM, (II) 32 
nM; mean 38 nM). 
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Figure S2. Growth Curves of P. aeruginosa PA14 
Strains were grown in the absence (▲)/presence of 5 μM compound 18 (■) or 19 (●). Samples were taken at 0h, 2.5h, 
4h, 5.5h, 6.5h, 8.5h and 9.5h to measure OD600. Mean value of one experiment with n = 3, standard deviation less than 
15%. 
 
 
Figure S3. Synthesis Route of HHQ and PQS Analogues 
Reagents and conditions: i) p-TsOH, n-hexane, reflux; (ii) Ph2O, reflux; iii) BF3• SMe2, DCM, r.t., then MeOH; iv) 
hexamine, p-TsOH, AcOH, reflux, then HCl/water; v) B(OH)3, conc. H2SO4, H2O2, THF, r.t.; vi) 
di-iso-propylethylamine, N-methylpyrrolidone, μW, 200 °C, 30-60 min. 
 
Supplemental Experimental Procedures 
 
Syntheses of the Title Compounds 1-21, 24 and 26-42 
Procedure A1.  
A solution of β-ketoester (9.24 mmol, 1 equiv), aniline (9.24 mmol, 1 equiv) and p-TsOH·H2O (50 
mg, 0.29 mmol, 3 mol %) in n-hexane (20 ml) was heated at reflux using a Dean-Stark separator for 
5 h. After cooling the solution was concentrated in vacuo and the residue was added dropwise to 
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refluxing (260 °C) diphenyl ether (5 ml). Refluxing was continued for 30 min. After cooling to 
room temperature, Et2O (15 ml) and 2 M HCl (20 ml) were added and the mixture was left 
overnight at 5 °C. If a crystalline solid had formed, it was collected and washed with Et2O. If no 
solid had formed, ammonia was added to basify the mixture. HHQ or its analogues was purified by 
crystallization from ethyl acetate or column chromatography on silica gel (Woschek et al., 2007). 
Procedure A2. 
A mixture of HHQ or its analogues (2.06 mmol, 1 equiv), hexamine (575 mg, 4.11 mmol, 2 equiv) 
and p-TsOH·H2O (400 mg, 2.32 mmol, 1.1 equiv) in glacial acetic acid (120 ml) was heated at 
reflux for 3 h under a nitrogen atmosphere. After cooling 5 M HCl (50 ml) was added and heating 
was continued at 105 °C for 1 h. The mixture was allowed to cool, diluted with water (200 ml), and 
extracted with CH2Cl2 (4 x 50 ml). The combined organic fractions were washed with brine, dried 
over MgSO4, and concentrated under reduced pressure. The crude 3-formyl-2-alkylquinolone was 
purified by column chromatography on silica gel (n-hexane/ethyl acetate, 5/9-1/1) (Tanoue et al., 
1989). 
Procedure A3. 
Boric acid (220 mg, 3.54 mmol, 5 equiv.) was suspended in THF (40 ml), followed by the addition 
of 30% H2O2 (in H2O, 0.24 ml, 3 equiv) and conc. H2SO4 (1.0 ml). After stirring for 30 min, a 
solution of 3-formyl-2-alkylquinolone (0.70 mmol, 1 equiv.) in THF (20 ml) was added dropwise 
over 10 min. After additional stirring for 5 h, the mixture was filtered. The filtrate was neutralized 
by addition of a sat. NaHCO3 solution (120 ml) and the aqueous layer was extracted with ethyl 
acetate (3 x 50 ml). After washing the combined organic fractions with brine and drying over 
MgSO4 the organic solvent was removed in vacuo. PQS or its analogues was purified by column 
chromatography on silica gel (CH2Cl2/MeOH, 60/1) (Gross et al., 2010). 
Procedure B.  
Di-iso-propylethylamine (1.31 mmol, 1.2 equiv) and 1-chlorononan-2-one (1.09 mmol, 1 equiv) 
were added to a solution of the appropriate substituted anthranilic acid (1.09 mmol, 1 equiv) in 
anhydrous N-methylpyrrolidone (2.25 ml) contained in a 10 ml microwave vial. The solution was 
then heated under microwave irradiation to 200 °C for 30-60 min. The reaction mixture was 
allowed to cool to room temperature, added to an ice/water mixture and left to settle for 20 min. The 
precipitate thus formed was isolated by filtration, dried in vacuo overnight and the PQS analogues 
was purified by recrystallization from ethyl acetate (Hodgkinson et al., 2011). 
Procedure C.  
To a solution of methoxy-substituted HHQ (0.36 mmol, 1 equiv) in anhydrous CH2Cl2 (8 ml) was 
added BF3·SMe2 complex (10 mmol, 30 equiv) at 0 °C and the reaction mixture was stirred at room 
temperature overnight. The reaction was quenched with MeOH, evaporated, and the residue was 
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purified by column chromatography on silica gel (CH2Cl2/MeOH, 40/1~25/1) (Konieczny et al., 
2005). 
 
2-Methylquinolin-4(1H)-one (1). Compound 1 was obtained according to procedure A1 from 
aniline (357 mg, 3.84 mmol) and 1a (500 mg, 3.84 mmol, commercial available) after 
crystallization as a brown solid (241 mg, 1.51 mmol, 39%), mp 234-235 °C. 
1
H-NMR (500 MHz, 
DMSO-d6): δ = 2.50 (s, 3H), 6.06 (s, 1H), 7.42 (t, J = 8.0 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.76 (dt, 
J = 1.5 Hz, 8.0 Hz, 1H), 8.19 (dd, J = 1.0 Hz, 8.0 Hz, 1H), 11.69 (brs, 1H). 
13
C-NMR (125 MHz, 
DMSO-d6): δ = 19.4, 108.3, 117.6, 122.6, 124.4, 124.7, 131.3, 140.0, 149.5, 176.6. LC/MS m/z 
160.12 (MH
+
), 99.9%.  
2-Pentylquinolin-4(1H)-one (2). Compound 2 was obtained according to procedure A1 from 
aniline (405 mg, 4.36 mmol) and 2a (811 mg, 4.36 mmol) after crystallization as a white solid (287 
mg, 1.33 mmol, 30%), mp 175-178 °C.
 1
H-NMR (500 MHz, DMSO-d6): δ = 0.87 (t, J = 7.0 Hz, 
3H), 1.32-1.35 (m, 4H), 1.76 (quint, J = 7.5 Hz, 2H), 2.99 (t, J = 7.5 Hz, 2H), 7.04 (s, 1H), 7.68 (t, J 
= 7.5 Hz, 1H), 7.96 (t, J = 7.5 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 8.25 (d, J = 7.0 Hz, 1H), 14.77 (brs, 
1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.8, 21.7, 28.4, 30.6, 33.2, 105.2, 119.3, 119.8, 123.4, 
126.6, 133.8 139.4, 159.8, 170.1. LC/MS: m/z 217.32 (MH
+
), 99.9%. 
2-Hexylquinolin-4(1H)-one (3). Compound 3 was obtained according to procedure A1 from 
aniline (785 mg, 8.44 mmol) and 3a (1.69 g, 8.44 mmol) after crystallization as a grey solid (933 
mg, 4.07 mmol, 48%), mp 142-143 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.82 (t, J = 7.0 Hz, 
3H), 1.24-1.32 (m, 6H), 1.72 (quint, J = 7.5 Hz, 2H), 2.98 (t, J = 7.5 Hz, 2H), 7.07 (s, 1H), 7.68 (t, J 
= 8.0 Hz, 1H), 7.96 (t, J = 7.5 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.23 (d, J = 8.5 Hz, 1H), 14.91 (brs, 
1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.8, 21.9, 28.1, 28.7, 30.8, 33.3, 105.1, 119.4, 119.6, 
123.4, 126.8, 133.9, 139.3, 160.1, 169.8. LC/MS: m/z 230.27 (MH
+
), 99.9%. 
2-Heptylquinolin-4(1H)-one (4). Compound 4 was obtained according to procedure A1 from 
aniline (859 mg, 9.24 mmol) and 4a (1.98 g, 9.24 mmol) after crystallization as a white solid (1320 
mg, 5.43 mmol, 59%), mp 149-151 °C. 
1
H-NMR (500 MHz, MeOH-d4): δ = 0.91 (t, J = 7.0 Hz, 
3H), 1.32-1.47 (m, 8H), 1.87 (quint, J = 7.5 Hz, 2H), 3.069 (t, J = 7.5 Hz, 2H), 7.04 (s, 1H), 7.78 (dt, 
J = 1.0 Hz, 8.5 Hz, 1H), 8.00 (d, J= 8.0 Hz, 1H), 8.04 (dt, J = 1.0 Hz, 8.5 Hz, 1H), 8.40 (d, J = 7.5 
Hz, 1H). 
13
C-NMR (125 MHz, MeOH-d4): δ = 14.4, 23.6, 30.0, 30.2, 30.4, 32.8, 35.4, 106.0, 120.3, 
120.9 125.0, 128.7, 135.9, 141.0, 162.7, 171.6. LC/MS: m/z 244.276 (MH
+
), 95.0%. 
2-Octylquinolin-4(1H)-one (5). Compound 5 was obtained according to procedure A1 from aniline 
(711 mg, 7.65 mmol) and 5a (1.744 g, 7.65 mmol) after crystallization as a white solid (537 mg, 
2.09 mmol, 27%), mp 132-135 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.80 (t, J = 7.0 Hz, 3H), 
1.19-1.32 (m, 10H), 1.71 (quint, J = 7.5 Hz, 2H), 2.97 (t, J = 7.5 Hz, 2H), 7.04 (s, 1H), 7.66 (t, J = 
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7.5 Hz, 1H), 7.94 (t, J = 7.0 Hz, 1H), 8.11 (d, J = 7.5 Hz, 1H), 8.22 (d, J = 7.5 Hz, 1H), 14.84 (brs, 
1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 14.4, 22.5, 28.9, 28.9, 29.0, 29.2, 31.6, 33.7, 105.6, 
119.8, 120.1, 123.9, 127.2, 134,3, 139.8, 160.5, 170.4. LC/MS: m/z 258.22 (MH
+
), 99.9%. 
2-Nonylquinolin-4(1H)-one (6). Compound 6 was obtained according to procedure A1 from 
aniline (960 mg, 10.33 mmol) and 6a (2.50 g, 10.33 mmol) after crystallization as a white solid 
(1.61 g, 5.96 mmol, 57%), mp 101-103 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.83 (t, J = 7.0 Hz, 
3H), 1.15-1.37 (m, 12H), 1.74 (quint, J = 7.5 Hz, 2H), 2.99 (t, J = 7.5 Hz, 2H), 7.04 (s, 1H), 7.69 (dt, 
J =1.0 Hz, 7.5 Hz, 1H), 7.97 (dt, J = 1.0 Hz, 7.5 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 8.25 (dd, J =1.0 
Hz, 8.5 Hz, 1H), 14.76 (brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.0, 22.0, 28.4, 28.59, 
28.62, 28.7, 28.8, 31.2, 33.3, 105.2, 119.3, 119.8, 123.5, 126.7, 133.8, 139.4, 159.9, 170.1. LC/MS: 
m/z 272.27 (MH
+
), 99.9%. 
2-(3-Phenylpropyl)quinolin-4(1H)-one (7). Compound 7 was obtained according to procedure A1 
from aniline (79 mg, 0.85 mmol) and 7a (200 mg, 0.85 mol). After cooling the reaction mixture was 
extracted with ethyl acetate. The combined organic phases were dried with MgSO4, and evaporated 
in vacuo. The residue was purified by chromatography on silica gel (CH2Cl2/MeOH, 25/1~30/1) 
yielding compound 7 (18 mg, 0.07 mmol, 8%) as a yellow solid, mp 168-170 °C. 
1
H-NMR (500 
MHz, MeOH-d4): δ = 2.04 (quint, J = 7.5 Hz, 2H), 2.69 (dt, J = 3.0 Hz, 7.5 Hz, 4H), 6.19 (s ,1H), 
7.12 (t, J = 7.5 Hz, 1H), 7.17 (d, J = 7.0 Hz, 2H), 7.23 (dt, J = 1.5 Hz, 7.5 Hz, 2H), 7.35 (dt, J = 1.5 
Hz, 7.5 Hz, 1H), 7.53 (d, J = 7.5 Hz, 1H), 7.64 (dt, J = 1.5 Hz, 7.5 Hz, 1H), 8.17 (dd, J = 0.5 Hz, 
8.0 Hz, 1H).
 13
C-NMR (125 MHz, MeOH-d4): δ = 30.3, 33.0, 34.8, 107.5, 117.6, 123.6, 124.1, 
124.5, 125.6, 128.0, 131.9, 140.2, 141.1, 155.2, 179.2. LC/MS: m/z 264.16 (MH
+
), 97.3%. 
2-Heptyl-7-hydroxyquinolin-4(1H)-one (8). Compound 8 was obtained according to procedure C 
from 9 (100 mg, 0.37 mol) after chromatography on silica gel as a white solid (42 mg, 0.17 mmol, 
46%), mp 138-141 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.86 (t, J = 6.5 Hz, 3H), 1.26-1.31 (m, 
8H), 1.64 (quint, J = 6.5 Hz, 2H), 2.53 (t, 3H), 5.76 (s, 1H), 6.72 (dd, J = 2.0 Hz, 9.0 Hz, 1H), 6.81 
(s, 1H), 7.85 (d, J = 8.5 Hz, 1H), 10.18 (s, 1H), 11.13 (s, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 
13.9, 22.0, 28.2, 28.3, 28.4, 31.1, 33.1, 100.8, 106.8, 113.2, 118.0, 126.6, 141.9, 152.7, 160.1, 176.5. 
LC/MS: m/z 260.20 (MH
+
), 99.9%. 
2-Heptyl-7-methoxyquinolin-4(1H)-one (9). Compound 9 was obtained according to procedure 
A1 from 3-methoxyaniline (260 mg, 2.11 mmol) and 4a (450 mg, 2.10 mmol) after chromatography 
on silica gel (CH2Cl2/MeOH, 20/1) as a yellow solid (171 mg, 0.63 mmol, 30%), mp 152-154 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.91 (t, J = 7.0 Hz, 3H), 1.29-1.37 (m, 8H), 1.68-1.74 (quint, J 
= 7.5 Hz, 2H), 2.59 (t, J = 7.5 Hz, 2H), 3.90 (s, 3H), 5.87 (s, 1H), 6.92 (dd, J = 2.5 Hz, 9.0 Hz, 1H), 
6.98 (d, J = 7.5 Hz, 1H), 7.98 (d, J = 9.0 Hz, 1H), 11.34 (brs, 1H).
 13
C-NMR (125 MHz, DMSO-d6): 
–55– 
δ = 13.8, 22.0, 28.2, 28.3, 28.4, 31.1, 33.1, 55.2, 98.8, 107.3, 112.5, 118.9, 126.5, 141.8, 152.9, 
161.6, 176.4. LC/MS: m/z 274.27 (MH
+
), 99.9%.  
2-Heptyl-8-methoxyquinolin-4(1H)-one (10). Compound 10 was obtained according to procedure 
A1 from 2-methoxyaniline (516 mg, 4.20 mmol) and 4a (900 mg, 4.20 mmol) after crystallization 
as a white solid (435 mg, 1.59 mmol, 38%), mp 105-108 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 
0.86 (t, J = 7.0 Hz, 3H), 1.25-1.31 (m, 8H), 1.62 (quint, J = 7.5 Hz, 2H), 2.66 (t, J = 7.5 Hz, 2H), 
3.98 (s, 3H), 5.91 (s, 1H), 7.19-7.21 (m, 2H), 7.60 (t, J = 8.0 Hz, 1H), 10.86 (brs, 1H). 
13
C-NMR 
(125 MHz, DMSO-d6): δ = 13.9, 22.0, 28.4, 28.5, 29.0, 31.2, 32.7, 56.1, 108.1, 111.0, 116.0, 117.1, 
122.4, 125.6, 130.8, 148.3, 153.7, 176.,5. LC/MS: m/z 274.26 (MH
+
), 96.3%. 
8-Ethyl-2-heptylquinolin-4(1H)-one (11). Compound 11 was obtained according to procedure A1 
from 2-ethylaniline (339 mg, 2.80 mmol) and 4a (600 mg, 2.80 mmol) after crystallization as a 
white solid (101 mg, 0.37 mmol, 13%), mp 103-104 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.85 
(t, J = 7.0 Hz, 3H), 1.21-1.32 (m, 11H), 1.65 (quint, J = 7.5 Hz, 2H), 2.70 (t, J = 7.5 Hz, 2H), 2.95 
(q, J = 7.5 Hz, 2H), 5.94 (s, 1H), 7.22 (t, J = 7.5 Hz, 1H), 7.46 (d, J = 7.0 Hz, 1H), 7.93 (d, J = 9.5 
Hz, 1H), 10.27 (brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.9, 14.2, 22.0, 23.1, 28.4, 28.5, 
28.9, 31.2, 32.9, 107.7, 122.6, 122.7, 125.0, 130.6, 131.8, 137.9, 154.2, 177.1. LC/MS: m/z 272.41 
(MH
+
), 99.9%. 
8-Fluoro-2-heptylquinolin-4(1H)-one (12). Compound 12 was obtained according to procedure 
A1 from 2-fluoroaniline (520 mg, 4.67 mmol) and 4a (1.00 g, 4.67 mmol) after crystallization as a 
yellow solid (371 mg, 1.42 mmol, 30%), mp 151-154 °C.
 1
H-NMR (500 MHz, DMSO-d6): δ = 0.85 
(t, J = 7.0 Hz, 3H), 1.24-1.31 (m, 8H), 1.64 (quint, J = 7.0 Hz, 2H), 2.64 (t, J = 7.0 Hz, 2H), 5.98 (s, 
1H), 7.25 (dt, J = 4.5 Hz, 8.0 Hz, 1H), 7.52 (m, 1H), 7.85 (dd, J = 1.0 Hz, 8.0 Hz, 1H), 11.42 (brs, 
1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.8, 22.0, 28.3, 28.5, 28.7, 31.1, 32.9, 108.3, 116.1 (d, 
JCF = 16.8 Hz), 120.4, 122.3 (d, JCF = 6.9 Hz), 126.7, 129.5, 151.5 (d, JCF = 249.6 Hz), 154,5, 175.8. 
LC/MS: m/z 262.21 (MH
+
), 97.8%. 
2-Heptyl-6-hydroxyquinolin-4(1H)-one (13). Compound 13 was obtained according to procedure 
C from 14 (100 mg, 0.37 mol) after chromatography on silica gel as a yellow solid (45 mg, 0.17 
mmol, 46%), mp 215-218 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.85 (t, J = 7.0 Hz, 3H), 
1.24-1.30 (m, 8H), 1.64 (quint, J = 7.0 Hz, 2H), 2.53 (t, J = 7.5 Hz, 2H), 5.79 (s, 1H), 7.09 (dd, J = 
3.0 Hz, 9.0 Hz, 1H), 7.351 (d, J = 3.5 Hz, 1H), 7.39 (d, J = 9.0 Hz, 1H), 9.54 (brs, 1H), 11.31 (brs, 
1H). 
13
C-NMR (125 MHz, DMSO-d6): δ =13.9, 22.0, 28.3, 28.4, 31.1, 33.1, 106.0, 107.3, 119.3, 
121.4, 126.0, 133.6, 152.1, 153.2, 176.2. LC/MS: m/z 260.23 (MH
+
), 99.9%. 
2-Heptyl-6-methoxyquinolin-4(1H)-one (14). Compound 14 was obtained according to procedure 
A1 from 4-methoxyaniline (517 mg, 4.20 mmol) and 4a (900 mg, 4.20 mmol) after crystallization 
(Et2O/MeOH) as a yellow solid (455 mg, 1.67 mmol, 40%), mp 140-141 °C. 
1
H-NMR (500 MHz, 
–56– 
DMSO-d6): δ = 0.85 (t, J = 7.0 Hz, 3H), 1.24-1.32 (m, 8H), 1.70 (quint, J = 7.0 Hz, 2H), 2.77 (t, J = 
8.0 Hz, 2H), 3.87 (s, 3H), 6.46 (s, 1H), 7.45 (dd, J = 2.5 Hz, 9.0 Hz, 1H), 7.50 (d, J = 3.0 Hz, 1H), 
7.77 (d, J = 9.0 Hz, 1H), 13.10 (brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.9, 22.0, 28.3, 
28.4, 28.6, 31.1, 33.2, 55.6, 102.9, 105.7, 120.4, 123.1, 123.7, 134.7, 156.4, 170.8. LC/MS: m/z 
274.27 (MH
+
), 97.5%. 
2-Heptyl-6-methylquinolin-4(1H)-one (15). Compound 15 was obtained according to procedure 
A1 from p-toluidine (400 mg, 3.74 mmol) and 4a (800 mg, 3.74 mmol) after chromatography on 
silica gel (CH2Cl2/MeOH, 30/1) as a yellow solid (194 mg, 0.74 mmol, 20%), mp 179-182 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.96 (t, J = 7.0 Hz, 3H), 1.35-1.42 (m, 8H), 1.77 (quint, J = 
7.0 Hz, 2H), 2.50 (s, 3H), 2.68 (t, J = 7.5 Hz, 2H), 6.00 (s, 1H), 7.55 (d, J = 1.0 Hz, 2H), 7.94 (s, 
1H), 11.53 (brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.8, 20.6, 22.0, 28.3, 28.4, 31.1, 33.1, 
107.3, 117.7, 124.0, 124.5, 131.8, 132.7, 138.1, 153.1, 176.7. LC/MS: m/z 258.27 (MH
+
), 99.9%. 
6-Fluoro-2-heptylquinolin-4(1H)-one (16). Compound 16 was obtained according to procedure 
A1 from 4-fluoroaniline (233 mg, 2.10 mmol) and 4a (450 mg, 2.10 mmol) after chromatography 
on silica gel (CH2Cl2/MeOH, 30/1~40/1) as a white solid (208 mg, 0.80 mmol, 38%), mp 
175-177 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.85 (t, J = 7.0 Hz, 3H), 1.25-1.32 (m, 8H), 1.67 
(quint, J = 7.5 Hz, 2H), 2.59 (t, J = 7.5 Hz, 2H), 5.94 (s, 1H), 7.52 (dt, J = 3.0 Hz, 8.0 Hz, 1H), 7.60 
(dd, J = 4.5 Hz, 9.0 Hz, 1H), 7.68 (dd, J = 3.0 Hz, 9.5 Hz, 1H), 11.62 (brs, 1H). 
13
C-NMR (125 
MHz, DMSO-d6):  δ = 13.8, 21.9, 28.3, 18.4, 31.0, 33.2, 106.8, 108.7(d, JCF = 22.2 Hz), 120.1 (d, 
JCF = 25.6 Hz), 120.5 (d, JCF = 8.2 Hz), 125.6 (d, JCF = 6.3 Hz), 136.8, 153.7, 158.0 (d, JCF = 240.8 
Hz), 175.9. LC/MS: m/z 262.23 (MH
+
), 99.9%. 
6-Chloro-2-heptylquinolin-4(1H)-one (17). Compound 17 was obtained according to procedure 
A1 from 4-chloroaniline (474 mg, 3.73 mmol) and 4a (800 mg, 3.74 mmol) after chromatography 
on silica gel (CH2Cl2/MeOH, 110/1) as a yellow solid (70 mg, 0.25 mmol, 7%), mp 220-223 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.84 (t, J = 7.0 Hz, 3H), 1.22-1.31 (m, 8H), 1.65 (quint, J = 
7.0 Hz, 2H), 2.58 (t, J= 7.5 Hz, 2H), 5.96 (s, 1H), 7.56 (d, J = 9.0 Hz, 1H), 7.64 (dd, J = 2.5 Hz, 9.0 
Hz, 1H), 7.96 (d, J = 2.5 Hz, 1H) 11.66 (brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.8, 21.9, 
28.2, 28.3, 28.4, 31.1, 33.2, 107.8, 120.3, 123.6, 125.5, 127.3, 131.5, 138.7, 154.1, 175.5. LC/MS: 
m/z 278.28 (MH
+
), 96.4%. 
2-Heptyl-8-methoxy-6-(trifluoromethyl)quinolin-4(1H)-one (21). Compound 21 was obtained 
according to procedure A1 from 2-methoxy-4-(trifluoromethyl)aniline (535 mg, 2.80 mmol) and 4a 
(600 mg, 2.80 mmol) after chromatography on silica gel (CH2Cl2/MeOH, 120/1~90/1) as a yellow 
solid (40 mg, 0.11 mmol, 4%), mp 168 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 1.66 (t, J = 7.0 Hz, 
3H), 2.03-2.12 (m, 8H), 2.43 (quint, J = 7.5 Hz, 2H), 3.50 (t, J = 7.5 Hz, 2H), 4.88(s, 3H), 6.86 (s, 
1H), 8.22 (d, J = 2.0 Hz, 1H), 8.71 (s, 1H), 12.07 (brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 
–57– 
16.6, 24.7, 31.1, 31.2, 31.6, 33.9, 35.4, 59.5, 109.3, 112.1, 116.2, 116.3, 116.3, 116.3, 125.5, 125.8, 
125.8, 127.3, 128.0, 136.0, 152.0, 157.8, 178.6. LC/MS: m/z 342.10 (MH
+
), 99.9%. 
2-Ethyl-6-(trifluoromethyl)quinolin-4(1H)-one (24). Compound 24 was obtained according to 
procedure A1 from 4-(trifluoromethyl)aniline (1.61 g, 10.0 mmol) and 24a (1.30 g, 10.0 mmol) 
after crystallization as a white solid (0.40 g, 1.66 mmol, 16%), mp 293-296 °C. 
1
H-NMR (500 MHz, 
DMSO-d6): δ = 1.26 (t, J = 7.6 Hz, 3H), 2.65 (q, J = 7.6 Hz, 2H), 6.05 (s, 1H), 7.71 (d, J = 8.9 Hz, 
1H), 7.91 (dd, J = 8.9 Hz, 2.1 Hz, 1H), 8.30 (s, 1H), 11.81 (brs, 1H). 
13
C-NMR (125 MHz, 
DMSO-d6): δ = 12.7, 26.4, 107.8, 119.4, 122.4 (q, JCF = 4.4 Hz), 123.0 (q, JCF = 32.0 Hz), 123.8, 
124.3 (q, JCF = 272.0 Hz), 127.4 (q, JCF = 3.5 Hz), 142.3, 156.0, 176.3. LC/MS: m/z 242.22 (MH
+
), 
99.4%. 
2-Butyl-6-(trifluoromethyl)quinolin-4(1H)-one (26). Compound 26 was obtained according to 
procedure A1 from 4-(trifluoromethyl)aniline (1.61 g, 10.0 mmol) and 26a  (1.58 g, 10.0 mmol) 
after crystallization as a white solid (1.87 g, 6.95 mmol, 69%), mp 225-226 °C. 
1
H-NMR (500 MHz, 
DMSO-d6): δ = 0.88 (t, J = 7.4 Hz, 3H), 1.32 (sextet, J = 7.5 Hz, 2H), 1.63 (quint, J = 7.6 Hz, 2H), 
2.59 (t, J = 7.7 Hz, 2H), 6.02 (s, 1H), 7.70 (d, J = 8.7 Hz, 1H), 7.87 (dd, J = 8.9 Hz, 2.1 Hz, 1H), 
8.30 (s, 1H), 11.80 (brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.5, 21.6, 30.2, 32.9, 108.7, 
119.5, 122.4 (q, JCF = 4.3 Hz), 123.0 (q, JCF = 32.0 Hz), 123.8, 124.2 (q, JCF = 272.0 Hz), 127.4 (q, 
JCF = 3.5 Hz), 142.2, 154.7, 176.2. LC/MS: m/z 270.28 (MH
+
), 99.7%. 
2-Pentyl-6-(trifluoromethyl)quinolin-4(1H)-one (27). Compound 27 was obtained according to 
procedure A1 from 4-(trifluoromethyl)aniline (1.61 g, 10.0 mmol) and methyl 27a (1.72 g, 10.0 
mmol) after crystallization as a white solid (1.23 g, 4.34 mmol 43%), mp 197-198 °C.
 1
H-NMR 
(500 MHz, DMSO-d6): δ = 0.86 (t, J = 7.1 Hz, 3H), 1.28-1.33 (m, 4H), 1.67 (m, 2H), 2.59 (t, J = 
7.7 Hz, 2H), 6.03 (s, 1H), 7.71 (d, J = 8.9 Hz, 1H), 7.89 (dd, J = 9.0 Hz, 2.1 Hz, 1H), 8.30 (d, J = 
1.6 Hz, 1H), 11.80 (brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.7, 21.7, 27.8, 30.6, 33.2, 
108.7, 119.5, 122.4 (q, JCF = 4.3 Hz), 123.0 (q, JCF = 32.0 Hz), 123.8, 124.3 (q, JCF = 272.0 Hz), 
127.4 (q, JCF = 3.4 Hz), 142.3, 154.8, 176.2. LC/MS: m/z 284.27 (MH
+
), 97.2%. 
2-Hexyl-6-(trifluoromethyl)quinolin-4(1H)-one (28). Compound 28  was obtained according to 
procedure A1 from 4-(trifluoromethyl)aniline (1.61 g, 10.0 mmol) and 28a (1.86 g, 10.0 mmol) 
after crystallization as a white solid (1.55 g, 5.22 mmol, 52%), mp 185 °C.
 1
H-NMR (500 MHz, 
DMSO-d6): δ = 0.83 (t, J = 7.1 Hz, 3H), 1.23-1.35 (m, 6H), 1.66 (quint, J = 7.5 Hz, 2H), 2.59 (t, J = 
7.7 Hz, 2H), 6.03 (d, J = 1.2 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.89 (dd, J = 8.9 Hz, 2.2 Hz, 1H), 
8.30 (d, J = 1.7 Hz, 1H), 11.80 (brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.8, 21.9, 28.1, 
30.9, 33.2, 108.7, 119.5, 122.4 (q, JCF = 4.6 Hz), 123.0 (q, JCF = 32.0 Hz), 123.8, 124.3 (q, JCF = 
272.0 Hz), 127.4 (q, JCF = 3.6 Hz), 142.3, 154.8, 176.2. LC/MS: m/z 298.32 (MH
+
), 99.5%. 
2-Heptyl-7-(trifluoromethyl)quinolin-4(1H)-one (29). Compound 29  was obtained according to 
–58– 
procedure A1 from 3-(trifluoromethyl)aniline (415 mg, 2.58 mmol) and 4a (600 mg, 2.80 mmol) 
after crystallization as a white solid (133 mg, 0.43 mmol, 16%), mp 218-220 °C.
 1
H-NMR (500 
MHz, DMSO-d6): δ = 0.84 (t, J = 7.0 Hz, 3H), 1.23-1.35 (m, 8H), 1.73 (quint, J = 7.5 Hz, 2H), 2.85 
(t, J = 7.5 Hz, 2H), 6.65 (s, 1H), 7.79 (d, J = 8.5 Hz, 1H), 8.27(s, 1H), 8.36 (d, J = 8.5 Hz, 1H) 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.9, 21.9, 28.3, 28.4, 31.0, 33.4, 107.6, 116.6 (q, JCF = 3.6 
Hz), 120.5(q, JCF = 3.6 Hz), 123.5(q, JCF = 272.0 Hz), 124.0, 126.2, 132.1 (q, JCF = 32.0 Hz), 139.2, 
158.8, 172.6. LC/MS: m/z 311.98 (MH
+
), 99.9%. 
2-Heptyl-8-(trifluoromethyl)quinolin-4(1H)-one (30). Compound 30  was obtained according to 
procedure A1 from 2-(trifluoromethyl)aniline (415 mg, 2.58 mmol) and 4a (600 mg, 2.80 mmol) 
after chromatography on silica gel (CH2Cl2/MeOH, 100/1) as a yellow solid (191 mg, 0.61 mmol, 
24%), mp 85-86 °C.
 1
H-NMR (500 MHz, DMSO-d6): δ = 0.83 (t, J = 7.0 Hz, 3H), 1.22-1.33 (m, 
8H), 1.87 (s, 2H), 2.78 (t, J = 7.5 Hz, 2H), 6.67 (brs, 1H), 7.49 (t, J = 7.5 Hz, 1H), 8.03 (d, J = 7.5 
Hz, 1H), 8.37 (J = 8.0 Hz, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.8, 21.9, 28.4, 28.5, 31.2, 
122.6 (not all signals of carbons were observed).  LC/MS: m/z 311.99 (MH
+
), 99.3%. 
3-Hydroxy-2-pentylquinolin-4(1H)-one (31). Compound 31 was obtained according to procedure 
A3 from 31a (95 mg, 0.39 mmol) after chromatography on silica gel as a white solid (25 mg, 0.11 
mmol, 28%), mp 259-263 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.93 (t, J = 7.0 Hz, 3H), 
1.37-1.40 (m, 4H), 1.73 (quint, J = 6.5 Hz, 2H), 2.78 (t, J = 7.5 Hz, 2H), 7.27 (quint, J = 9.0 Hz, 
1H), 7.58 (d, J = 3.5 Hz, 2H), 8.14 (d, J = 7.5 Hz, 1H), 11.46 (brs, 1H). 
13
C-NMR (125 MHz, 
DMSO-d6): δ = 13.8, 21.8, 27.4, 28.0, 30.9, 117.7, 121.4, 122.1, 124.4, 129.9, 135.3, 137.3, 137.7, 
168.8. LC/MS: m/z 232.24 (MH
+
), 96.4%. 
2-Hexyl-3-hydroxyquinolin-4(1H)-one (32). Compound 32 was obtained according to procedure 
A3 from 32a (288 mg, 1.12 mmol) after chromatography on silica gel as a light brown solid (86 mg, 
0.35 mmol, 31%), mp 203-205 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.81 (t, J = 7.0 Hz, 3H), 
1.21-1.32 (m, 6H), 1.62 (quint, J = 7.5 Hz, 2H), 2.69 (t, J = 7.5 Hz, 2H), 7.17 (quint, J = 4.0 Hz, 
1H), 7.49 (d, J = 4.0 Hz, 2H), 8.05 (d, J = 8.0 Hz, 1H), 11.36 (brs, 1H). 
13
C-NMR (125 MHz, 
DMSO-d6): δ = 14.4, 22.5, 28.2, 28.6, 28.9, 31.5, 118.2, 121.9, 122.6, 124.9, 130.4, 135.9, 137.8, 
138.3, 169.3. LC/MS: m/z 246.23 (MH
+
), 98.7%. 
2-Heptyl-3-hydroxyquinolin-4(1H)-one (33). Compound 33 was obtained according to procedure 
A3 from 33a (190 mg, 0.70 mmol) after chromatography on silica gel as a white solid (73 mg, 0.28 
mmol, 40%), mp 195-198 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.84 (t, J = 7.0 Hz, 3H), 
1.22-1.34 (m, 8H), 1.66 (quint, J = 7.0 Hz, 2H), 2.72 (t, J = 7.5 Hz, 2H), 7.21 (quint, J = 4.0 Hz, 
1H), 7.52 (d, J = 3.5 Hz, 2H), 8.08 (d, J = 8.0 Hz, 1H), 11.41 (brs, 1H). 
13
C-NMR (125 MHz, 
DMSO-d6): δ = 13.9, 22.0, 27.8, 28.1, 28.4, 28.7, 31.2, 117.7, 121.5, 122.1, 124.4, 129.9, 135.5, 
137.3, 137.8, 168.8. LC/MS: m/z 260.25 (MH
+
), 97.1%. 
–59– 
3-Hydroxy-2-octylquinolin-4(1H)-one (34). Compound 34 was obtained according to procedure 
A3 from 34a (243 mg, 0.85 mmol) after chromatography on silica gel as a light brown solid (116 
mg, 0.42 mmol, 49%), mp 192-194 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.84 (t, J = 7.0 Hz, 
3H), 1.24-1.34 (m, 10H), 1.66 (quint, J = 7.5 Hz, 2H), 2.72 (t, J = 7.5 Hz, 2H), 7.21 (quint, J = 4.0 
Hz, 1H), 7.52 (d, J = 4.0 Hz, 2H), 8.08 (d, J = 8.0 Hz, 1H), 11.38 (brs, 1H). 
13
C-NMR (125 MHz, 
DMSO-d6): δ = 13.9, 22.0, 27.7, 28.0, 28.6, 28.7, 28.8, 31.2, 117.7, 121.4, 122.1, 124.4, 129.9, 
135.4, 137.3, 137.8, 168.8. LC/MS: m/z 274.29 (MH
+
), 99.9%. 
3-Hydroxy-2-nonylquinolin-4(1H)-one (35). Compound 35 was obtained according to procedure 
A3 from 35a (240 mg, 0.80 mmol) after chromatography on silica gel as a white solid (113 mg, 
0.42 mmol, 39%), mp 167-169 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.84 (t, J = 7.0 Hz, 3H), 
1.18-1.35 (m, 12H), 1.66 (quint, J = 7.5 Hz, 2H), 2.72 (t, J = 7.5 Hz, 2H), 7.21 (quint, J = 4.0 Hz, 
1H), 7.52 (d, J = 3.5 Hz, 2H), 8.08 (d, J = 8.5 Hz, 1H), 11.38 (brs, 1H). 
13
C-NMR (125 MHz, 
DMSO-d6): δ = 13.9, 22.0, 27.7, 28.1, 28.6, 28.8, 28.9, 31.2, 117.7, 121.4, 122.1, 124.4, 129.9, 
135.4, 137.3, 137.8, 168.8. LC/MS m/z 288.37 (MH
+
), 99.9%. 
2-Heptyl-3-hydroxy-6-methoxyquinolin-4(1H)-one (36). Compound 36 was obtained according 
to procedure A3 from 36a (210 mg, 0.70 mmol) after chromatography on silica gel as a brown solid 
(79 mg, 0.27 mmol, 38%), mp 211-214 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.84 (t, J = 7.0 Hz, 
3H), 1.23-1.31 (m, 8H), 1.65 (quint, 2H), 2.71 (t, 2H), 3.82 (s, 3H), 7.18 (dd, J = 2.0 Hz, 6.0 Hz, 
1H), 7.4-7.48 (br, 2H), 11.40 (brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.8, 22.0, 27.8, 28.1, 
28.4, 28.7, 31.1, 55.2, 102.8, 119.5, 121.2, 122.8, 132.3, 134.8, 137.3, 154.3, 167.8. LC/MS: m/z 
290.24 (MH
+
), 99.9%. 
2-Heptyl-3-hydroxy-7-methoxyquinolin-4(1H)-one (37). Compound 37 was obtained according 
to procedure A3 from 37a (240 mg, 0.80 mmol) after chromatography on silica gel as a brown solid 
(218 mg, 0.75 mmol, 94%), mp 222-224 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.85 (t, J = 7.0 
Hz, 3H), 1.25-1.31 (m, 8H), 1.65 (m, 2H), 2.68 (m, 2H), 3.83 (s, 3H), 6.82 (d, J = 9.0 Hz, 1 H), 6.91 
(br. 1H), 7.82 (br, 1H), 7.97 (d, J = 9.0 Hz, 1H), 11.18 (brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): 
δ = 13.8, 22.0, 27.7, 27.9, 28.4, 28.6, 31.1, 55.2, 97.8, 112.5, 116.6, 126.1, 134.3, 137.2, 139.0, 
160.7, 168.7. LC/MS: m/z 290.24 (MH
+
), 99.9%. 
8-Fluoro-2-heptyl-3-hydroxyquinolin-4(1H)-one (38). Compound 38 was obtained according to 
procedure A3 from 38a (68 mg, 0.23 mmol) after chromatography on silica gel as a brown solid (21 
mg, 0.08 mmol, 35%), mp 167-169 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.84 (t, J = 7.0 Hz, 
3H), 1.23-1.35 (m, 8H), 1.63 (quint, J= 7.5 Hz, 2H), 2.79 (t, J = 7.5 Hz, 2H), 7.16-7.20 (m ,1H), 
7.43-7.46 (m, 1H), 7.91 (d, J = 8.0 Hz, 1H), 8.20 (brs, 1H), 11.93 (s 1H). 
13
C-NMR (125 MHz, 
DMSO-d6): δ = 13.893, 22.023, 27.710, 27.998, 28.428, 28.823, 31.181, 114.1, 114.2, 117.1, 117.7, 
–60– 
120.2, 120.3, 121.0, 124.4,125.9, 125.9, 126.6, 126.8, 136.4, 138.5, 151.4(d, JCF = 247.8 Hz), 168.3. 
LC/MS: m/z 278.23, 99.0%. 
6-Fluoro-2-heptyl-3-hydroxyquinolin-4(1H)-one (39). Compound 39 was obtained according to 
procedure A3 from 39a (172 mg, 0.59 mmol) after chromatography on silica gel as a pink solid 
(140 mg, 0.50 mmol, 85%), mp 228-231 °C.
 1
H-NMR (500 MHz, DMSO-d6): δ = 0.84 (t, J = 7.0 
Hz, 3H), 1.24-1.32 (m, 8H), 1.66 (quint, J = 6.5 Hz, 2H), 2.72 (t, J = 6.5 Hz, 2H), 7.44 (t, J = 6.5 
Hz, 1H), 7.60 (brs, 1H), 7.70 (dd, J = 3.0 Hz, 6.5 Hz, 1H), 8.13 (brs, 1H). 
13
C-NMR (125 MHz, 
DMSO-d6): δ = 13.8, 22.0, 27.7, 28.1, 28.4, 28.7, 31.1, 107.8 (d, JCF = 21.9 Hz), 119.1(d, JCF = 25.8 
Hz), 120.4(d, JCF = 8.2 Hz), 122.9(d, JCF = 6.8 Hz), 134.1, 136.1, 137.5, 157.2 (d, JCF = 240.1 Hz), 
167.9, 167.9. LC/MS: m/z 278.22 (MH
+
), 99.9%. 
2-Heptyl-3-hydroxy-6-methylquinolin-4(1H)-one (40). Compound 40 was obtained according to 
procedure A3 from 40a (150 mg, 0.52 mmol) after chromatography on silica gel as a white solid 
(118 mg, 0.43 mmol, 83%), mp 221-222 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.95 (t, J = 7.0 
Hz, 3H), 1.34-1.45 (m, 8H), 1.76 (quint, J = 7.5 Hz, 2H), 2.50 (s, 3H), 2.82 (t, J= 7.5 Hz, 2H), 7.47 
(dd, J = 2.0 Hz, 8.5 Hz, 1H), 7.55 (d, J = 8.5 Hz, 1H), 7.98 (s, 1H) 11.46 (br, 1H). 
13
C-NMR (125 
MHz, DMSO-d6): δ = 13.8, 20.6, 22.0, 27.7, 28.4, 28.7, 31.1, 117.6, 122.0, 123.3, 130.6, 131.6, 
135.2, 135.5, 137.6, 168.4. LC/MS: m/z 274.32 (MH
+
), 95.4%. 
2-Heptyl-3-hydroxy-6-iodoquinolin-4(1H)-one (41). Compound 41 was obtained according to 
procedure B from 1-chlorononan-2-one (192 mg, 1.10 mmol) and 2-amino-5-iodobenzoic acid (288 
mg, 1.10 mmol) after recrystallisation as a grey solid (70 mg, 0.18 mmol, 16%), mp 275-279 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.83 (t, J = 7.0 Hz, 3H), 1.23-1.31 (m, 8H), 1.64 (quint, J = 
7.5 Hz, 2H), 2.70 (t, J= 7.5 Hz, 2H), 7.36 (d, J = 6.0 Hz, 1H), 7.77 (dd, J = 2.0 Hz, 8.5 Hz, 1H), 
8.38 (d, J = 2.5 Hz, 1H) 11.57 (brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.8, 21.9, 27.6, 
28.1, 28.3, 28.6, 31.1, 85.6, 120.2, 124.1, 132.8, 136.2, 136.3, 137.8, 138.2, 167.4. LC/MS: m/z 
386.19 (MH
+
), 99.1%. 
2-Heptyl-3-hydroxybenzo[g]quinolin-4(1H)-one (42). Compound 42 was obtained according to 
procedure B from 1-chlorononan-2-one (192 mg, 1.10 mmol) and 3-amino-2-naphthoic acid (151 
mg, 1.10 mmol) after chromatography on silica gel as a yellow solid (15mg, 0.05 mmol, 4%), mp 
250-253 °C. 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.90 (t, J = 7.0 Hz, 3H), 1.29-1.49 (m, 8H), 1.84 
(quint, J = 7.5 Hz, 2H), 2.95 (t, J= 7.5 Hz, 2H), 7.44 (t, J = 7.5 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 
7.92 (d, J = 8.5 Hz, 1H), 8.05 (m, 2H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 14.3, 23.6, 29.3, 30.1, 
30.2, 30.5, 32.8, 114.9, 123.5, 125.6, 126.0, 128.0, 128.6, 130.1, 130.6, 135.7, 142.6, 171.6. LC/MS: 
m/z 310.35 (MH
+
), 96.6%. 
For synthesis of compounds 18-20 see the experimental procedures of the paper. 
Compounds 22, 23 and 25 were commercially available. 
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Syntheses of the Intermediates 2a-7a, 27a-28a and 31a-40a 
Procedure D.  
Sythesis of ethyl β-ketoester. To a THF solution of 2M LDA (20 ml, 40 mmol 2.4 equiv) was added 
ethyl acetoacetate (16.6 mmol, 1.0 equiv) at 0 °C. The deep yellow clear solution was stirred at 0 °C 
for 1 h. To this solution the alkyl halide was added (20.0 mmol 1.2 equiv) at -78 °C. The 
temperature was allowed to reach an ambient temperature over 14 h and the solution was stirred at 
r.t. for 2 h. To the solution was added 10% HCl (200 ml) and the mixture was extracted with Et2O 
(4 × 250 ml). The combined organic layers were dried over Na2SO4, filtered, and the filtrate was 
concentrated in vacuo. The residue was purified by column chromatography (n-hexane/ethyl acetate, 
30/1) to give ethyl β-ketoester (Nguyen et al., 2006). 
Procedure E.  
Sythesis of methyl β-ketoester. A solution of methyl akylnyl ester (30.0 mmol, 1 equiv) and 
piperidine (30.0 mmol, 1 equiv) in benzene (10 ml) was heated overnight under reflux. After 
evaporation of the solvent under reduced pressure the residue was purified by flash column 
chromatography on silica (ethyl acetate/n-hexanes 15/85) twice to yield methyl β-ketoester 
(Bestmann et al., 1977). 
Ethyl 3-oxooctanoate (2a). Compound 2a was obtained according to procedure D from ethyl 
acetoacetate (2.57 g, 16.60 mmol) and 1-iodobutane (3.68 g, 19.89 mmol) after chromatography on 
silica gel as a yellow oil (811 mg, 4.36 mmol, 26%). 
1
H-NMR (500 MHz, CDCl3): δ = 0.82 (t, J = 
7.0 Hz, 3H), 1.17-1.28 (m, 7H), 1.53 (quint, J = 7.5 Hz, 2H), 2.46 (t, J = 7.5 Hz, 2H), 3.35 (s, 2H), 
4.12 (q, J = 8.0 Hz 2H). 
13
C-NMR (125 MHz, CDCl3): δ = 13.8, 14.0, 22.3, 23.1, 31.1, 42.9, 49.2, 
61.2, 167.2, 202.9. LC/MS: m/z 344.39, 93.3%. 
Ethyl 3-oxononanoate (3a). Compound 3a was obtained according to procedure D from 
ethylacetoactate (2.57 g, 16.60 mmol) and 1-iodopentane (3.96 g, 20.00 mmol) after 
chromatography on silica gel as a yellow oil (1.69 g, 9.08 mmol, 55%). 
1
H-NMR (500 MHz, 
CDCl3): δ = 0.81 (t, J = 7.0 Hz, 3H), 1.19-1.25 (m, 9H), 1.52 (quint, J = 7.5 Hz, 2H), 2.46 (t, J = 7.5 
Hz, 2H), 3.35 (s, 2H), 4.11 (m, 2H). 
13
C-NMR (125 MHz, CDCl3): δ = 13.9, 14.0, 22.4, 23.4, 28.6, 
31.5, 43.0, 49.2, 61.2, 167.2, 202.9. LC/MS: m/z 372.44, 94.1%. 
Ethyl 3-oxodecanoate (4a). Compound 4a was obtained according to procedure D from 
ethylacetoactate (2.16 g, 16.60 mmol) and 1-iodohexane (4.20 g, 19.81 mmol) after 
chromatography on silica gel as a yellow oil (1.98 g, 9.24 mmol, 55%). 
1
H-NMR (500 MHz, 
CDCl3): δ = 0.84 (t, J = 7.0 Hz, 3H), 1.23-1.28 (m, 11H), 1.54 (quint, J = 7.0 Hz, 2H), 2.49 (t, J = 
7.0 Hz, 2H), 3.39 (s, 2H), 4.16 (m, 2H). 
13
C-NMR (125 MHz, CDCl3): δ = 13.9, 14.0, 22.5, 23.4, 
28.9, 31.5, 43.0, 49.2, 61.2, 167.2, 202.9. LC/MS: m/z 457.98, 87.1%. 
Ethyl 3-oxoundecanoate (5a). Compound 5a was obtained according to procedure D from 
ethylacetoactate (2.57 g, 16.60 mmol) and 1-iodoheptane (4.48 g, 19.83 mmol) after 
–62– 
chromatography on silica gel as a yellow oil (1.74 g, 7.65 mmol, 46%). 
1
H-NMR (500 MHz, 
CDCl3): δ = 0.80 (t, J = 7.0 Hz, 3H), 1.19-1.25 (m, 13H), 1.52 (quint, J = 7.5 Hz, 2H), 2.45 (t, J = 
7.5 Hz, 2H), 3.35 (s, 2H), 4.12 (q, J = 7.5 Hz, 2H). 
13
C-NMR (125 MHz, CDCl3): δ = 14.0, 14.0, 
22.6, 23.4, 29.0, 29.0, 29.2, 31.7, 43.0, 49.3, 61.3, 167.2, 202.9. LC/MS: m/z 237.31, 99.9%. 
Ethyl 3-oxododecanoate (6a). Compound 6a was obtained according to procedure D from 
ethylacetoactate (2.57 g, 16.60 mmol) and 1-iodooctane (7.40 g, 20.00 mmol) after chromatography 
on silica gel as a yellow oil (2.50 g, 10.33 mmol, 62%). 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.85 (t, 
J = 7.0 Hz, 3H), 1.16-1.28 (m, 15H), 1.45 (quint, J = 7.0 Hz, 2H), 2.49 (t, J = 7.0 Hz, 2H, 
overlapped with peak of solution), 3.55 (s, 2H), 4.08 (q, J = 7.0 Hz, 2H). 
13
C-NMR (125 MHz, 
DMSO-d6): δ = 13.8, 13.9, 22.0, 22.8, 28.3, 28.6, 28.7, 28.8, 31.2, 42.1, 48.7, 60.4, 167.2, 203.5. 
LC/MS: m/z 372.41, 96.4%. 
Ethyl 3-oxo-6-phenylhexanoate (7a). To a stirred solution of 4-phenylbutyric acid (800 mg, 4.88 
mmol, 1 equiv) and SOCl2 (4 ml, 54.69 mmol, 11.2 equiv) was added pyridine (0.3 ml, 3.71 mmol, 
0.76 equiv). The solution was stirred at room temperature for 30 min and at 40 °C for an additional 
1 h before it was concentrated to give 4-phenylbutanoylchloride as a yellow oil, which was used in 
the next step without further purification (Muhlman et al., 2001). Under a nitrogen atmosphere 
monoethyl malonate (1.20 g, 9.09 mmol) and 2,2'-bipyridyl (8 mg, as an indicator) were added to a 
solution of THF (25 ml). After cooling to -70 °C, n-butyllithium (1.6 M, in n-hexane, 12 ml, 19.2 
mmol) was added slowly while allowing the temperature to rise to ca. -5 °C near the end of the 
addition. After the pink color persisted at -5 °C the heterogeneous solution was recooled to -70 °C 
and 4-phenylbutanoylchloride (4.88 mmol) was added over 5 min. Stirring was continued at -70 °C 
for 1 h. The reaction solution was poured into a mixture of ether (40 ml) and HCl (1.0 M, 20 ml). 
After mixing and separating the aqueous phase, the organic phase was washed with saturated 
sodium bicarbonate and water, dried over Na2SO4, and concentrated in vacuo to yield 7a (150 mg, 
0.64 mmol, 13%) as a yellow oil (Wierenga et al., 1979). 
1
H-NMR (500 MHz, DMSO-d6): δ = 1.14 
(t, J = 7.0 Hz, 3H), 1.73 (quint, J = 7.5 Hz, 2H), 2.50 (q, J = 7.5 Hz, 4H), 3.28 (s, 1H), 3.52 (s, 2H), 
4.04 (q, J = 7.0 Hz, 2H), 7.13-7.15 (m, 3H), 7.23-7.26 (m, 2H). 
13
C-NMR (125 MHz, DMSO-d6): δ 
= 13.9, 24.6, 34.2, 41.5, 48.7, 60.4, 125.7, 128.2, 141.5, 167.2, 203.3. LC/MS: m/z 415.26, 97.7%.  
Methyl 3-oxooctanoate ester (27a). Compound was obtained according to procedure E from 
methyl 2-octynoate (4.63 g, 30.0 mmol) after chromatography on silica gel as a colorless oil (3.00 g, 
17.44 mmol, 58%).  
1
H-NMR (500 MHz, CDCl3): δ = 0.88 (t, J = 7.1 Hz, 3H), 1.29 (m, 4H), 1.59 
(m, 2H), 2.52 (t, J = 7.4 Hz, 2H), 3.44 (s, 2H), 3.73 (s, 3H). 
Methyl 3-oxononanoate (28a). Compound was obtained according to procedure E from methyl 
2-nonynoate (5.05 g, 30 mmol) after chromatography on silica gel as a colorless oil (2.96 g, 15.91 
mmol, 53%). 
1
H-NMR (500 MHz, CDCl3): δ = 0.85 (t, J = 6.9 Hz, 3H), 1.25 (m, 6H), 1.56 (m, 2H), 
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2.50 (t, J = 7.4 Hz, 2H), 3.42 (s, 2H), 3.71 (s, 3H). 
4-Oxo-2-pentyl-1,4-dihydroquinoline-3-carbaldehyde (31a). Compound 31a was obtained 
according to procedure A2 from 2 (224 mg, 1.03 mmol) after chromatography on silica gel as a 
yellow solid (105 mg, 0.43 mmol, 42%). 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.88 (t, J = 7.0 Hz, 
3H), 1.32-1.37 (m, 4H), 1.60 (quint, J = 7.5 Hz, 2H), 3.04 (t, J= 7.5 Hz, 2H), 7.42 (t, J = 7.0 Hz, 
1H), 7.59 (d, J = 8.0 Hz, 1H), 7.73 (m, 1H), 8.14 (dd, J = 1.5 Hz, 8.5 Hz, 1H), 10.38 (s, 1H), 12.11 
(brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.7, 21.7, 28.4, 31.1, 314, 113.3, 118.7, 124.9, 
126.1, 133.0, 139.1, 160.0, 178.0, 190.7. LC/MS: 244.23 (MH
+
), 99.9% 
2-Hexyl-4-oxo-1,4-dihydroquinoline-3-carbaldehyde (32a). Compound 32a was obtained 
according to procedure A2 from 3 (500 mg, 2.18 mmol) after chromatography on silica gel as a 
yellow solid (298 mg, 1.16 mmol, 53%). 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.86 (t, J = 7.0 Hz, 
3H), 1.27-1.41 (m, 6H), 1.59 (quint, J = 7.5 Hz, 2H), 3.04 (t, J= 8.0 Hz, 2H), 7.42 (t, J = 8.0 Hz, 
1H), 7.59 (d, J = 8.0 Hz, 1H), 7.73 (m, 1H), 8.14 (dd, J = 1.0 Hz, 8.0 Hz, 1H) 10.38 (s, 1H) 12.13 
(brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.8, 21.9, 28.6, 28.7, 30.8, 31.5, 113.3, 118.6, 
124.9, 126.1, 133.0, 139.1, 160.0, 178.0, 190.7. LC/MS: 258.24 (MH
+
), 99.9% 
2-Heptyl-4-oxo-1,4-dihydroquinoline-3-carbaldehyde (33a). Compound 33a was obtained 
according to procedure A2 from 4 (500 mg, 2.06 mmol) after chromatography on silica gel as a 
yellow solid (310 mg, 1.14 mmol, 55%). Compound 33a was unstable, decomposition was 
observed in 
1
H-NMR test. LC/MS: 272.22 (MH
+
), 99.9%. 
2-Octyl-4-oxo-1,4-dihydroquinoline-3-carbaldehyde (34a). Compound 34a was obtained 
according to procedure A2 from 5 (500 mg, 1.94 mmol) after chromatography on silica gel as a 
yellow solid (243 mg, 0.85 mmol, 44%). 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.84 (t, J = 7.0 Hz, 
3H), 1.15-1.40 (m, 10H), 1.59 (quint, J = 7.5 Hz, 2H), 3.06 (t, J= 8.0 Hz, 2H), 7.42 (t, J = 8.0 Hz, 
1H), 7.59 (d, J = 8.0 Hz, 1H), 7.73 (m, 1H), 8.14 (dd, J = 1.5 Hz, 8.5 Hz, 1H), 10.38 (s, 1H), 12.11 
(brs, 1H).
 13
C-NMR (125 MHz, DMSO-d6): δ = 13.9, 22.0, 28.5, 28.6, 28.8, 29.0, 31.2, 31.5, 113.3, 
118.6, 124.9, 126.1, 133.0, 139.1, 160.0, 178.1, 190.8. LC/MS: 286.29 (MH
+
), 99.9%. 
2-Nonyl-4-oxo-1,4-dihydroquinoline-3-carbaldehyde (35a). Compound 35a was obtained 
according to procedure A2 from 6 (500 mg, 1.84 mmol) after chromatography on silica gel as a 
yellow solid (252 mg, 0.84 mmol, 46%). 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.84 (t, J = 7.0 Hz, 
3H), 1.24-1.27 (m, 12H), 1.59 (quint, J = 7.5 Hz, 2H), 3.04 (t, J= 7.5 Hz, 2H), 7.42 (t, J = 8.0 Hz, 
1H), 7.59 (d, J = 8.0 Hz, 1H), 7.73 (m, 1H), 8.14 (dd, J = 1.5 Hz, 8.5 Hz, 1H), 10.38 (s, 1H), 12.11 
(brs, 1H). 
13
C-NMR (125 MHz, DMSO-d6): δ = 13.9, 22.0, 28.6, 28.6, 28.8, 28.9, 31.3, 113.3, 118.6, 
124.9, 126.1, 133.0, 139.1, 160.0, 178.0, 190.7. LC/MS: 300.28 (MH
+
), 98.3%. 
2-Heptyl-6-methoxy-4-oxo-1,4-dihydroquinoline-3-carbaldehyde (36a). Compound 36a was 
obtained according to procedure A2 from 14 (350 mg, 1.28 mmol) after chromatography on silica 
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gel as a yellow solid (210 mg, 0.70 mmol, 54%). 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.85 (t, J = 
7.0 Hz, 3H), 1.25-1.38 (m, 8H), 1.58 (quint, J = 7.5 Hz, 2H), 3.02 (t, J = 8.0 Hz, 2H), 3.85 (s, 3H), 
7.36 (dd, J = 3.0 Hz, 9.0 Hz, 1H), 7.54-7.56 (m, 2H), 10.39 (s, 1H), 12.10 (brs, 1H). 
13
C-NMR (125 
MHz, DMSO-d6): δ =13.8, 22.0, 28.3, 28.8, 28.9, 31.1, 31.5, 55.4, 104.9, 112.5, 120.4, 122.6, 127.4, 
133.5, 156.6, 158.4, 177.5, 190.7. LC/MS: 302.25 (MH
+
), 99.9%. 
2-Heptyl-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carbaldehyde (37a).Compound 37a was 
obtained according to procedure A2 from 9 (580 mg, 2.13 mmol) after chromatography on silica gel 
as a yellow solid (250 mg, 0.83 mmol, 39%). 
1
H-NMR (500 MHz, DMSO-d6): δ = 1.06 (t, J = 7.0 
Hz, 3H), 1.46-1.59 (m, 8H), 1.79 (quint, J = 7.5 Hz, 2H), 3.22 (t, J= 7.5 Hz, 2H), 4.08 (s, 3H), 
7.18-7.22 (m, 2H), 8.24 (d, J = 7.5 Hz, 1H), 10.56 (s, 1H), 12.15 (brs, 1H). 
13
C-NMR (125 MHz, 
DMSO-d6): δ = 13.8, 21.9, 28.2, 28.7, 28.9, 31.0, 31.4, 55.5, 100.2, 113.1, 114.2, 120.0, 126.8, 
140.9, 159.9, 162.7, 177.4, 190.8, 190.9. LC/MS: 302.22 (MH
+
), 99.9%. 
8-Fluoro-2-heptyl-4-oxo-1,4-dihydroquinoline-3-carbaldehyde (38a). Compound 38a was 
obtained according to procedure A2 from 12 (305 mg, 1.17 mmol) after chromatography on silica 
gel as a yellow solid (68 mg, 0.23 mmol, 20%).Compound 27a was unstable, decomposition was 
observed in 
1
H-NMR test. LC/MS: 264.17 (MH
+
), 98.0%. 
6-Fluoro-2-heptyl-4-oxo-1,4-dihydroquinoline-3-carbaldehyde (39a). Compound 39a was 
obtained according to procedure A2 from 16 (290 mg, 1.11 mmol) after chromatography on silica 
gel as a yellow solid (182 mg, 0.63 mmol, 56%). 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.86 (t, J = 
7.0 Hz, 3H), 1.23-1.42 (m, 8H), 1.60 (quint, J = 7.5 Hz, 2H), 3.04 (t, J= 7.5 Hz, 2H), 7.62-7.69 (m, 
2H), 7.80 (dd, J = 3.0 Hz, 9.5 Hz, 1H) 10.38 (s, 1H), 12.26 (brs, 1H). 
13
C-NMR (125 MHz, 
DMSO-d6): δ = 13.8, 21.9, 28.2, 28.7, 28.9, 31.0, 31.6, 109.5, 111.9, 112.7, 121.5, 127.6, 136.0, 
158.9 (d, JCF = 244.1 Hz), 177.2, 190.6. LC/MS: 290.22 (MH
+
), 95.7%. 
2-Heptyl-6-methyl-4-oxo-1,4-dihydroquinoline-3-carbaldehyde (40a). Compound 40a was 
obtained according to procedure A2 from 15 (300 mg, 1.17 mmol) after chromatography on silica 
gel as a yellow solid (161 mg, 0.56 mmol, 48%). 
1
H-NMR (500 MHz, DMSO-d6): δ = 0.93 (t, J = 
7.0 Hz, 3H), 1.30-1.48 (m, 8H), 1.66 (quint, J = 7.5 Hz, 2H), 2.50 (s, 3H), 3.10 (t, J = 8.0 Hz, 2H), 
7.57 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 2.0 Hz, 8.5 Hz, 1H), 8.01 (s, 1H), 10.458 (s, 1H). 
13
C-NMR 
(125 MHz, DMSO-d6): δ = 13.8, 20.7, 21.9, 28.2, 28.8, 28.9, 31.0, 31.5, 113.1, 118.6, 124.3, 126.1, 
134.2, 134.5, 137.1, 159.4, 177.9, 190.7. LC/MS: 286.33 (MH
+
), 99.7%. 
Intermediates 1a, 24a and 26a were commercially available. 
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6.2 Supplemental Information for Paper II 
 
General Experimental Information-Chemistry 
 
Chemicals and Analytical Methods 
1
H and 
13
C NMR spectra were recorded on a Bruker DRX-500 instrument. Chemical shifts are 
given in parts per million (ppm) with the solvent resonance as internal standard for spectra obtained 
in CDCl3, MeOH-d4 and DMSO-d6. All coupling constants (J) are given in hertz. Mass 
spectrometry (LC/MS) was performed on a MSQ
®
 electro spray mass spectrometer (Thermo Fisher). 
The system was operated by the standard software Xcalibur®. A RP C18 NUCLEODUR
®
 100-5 
(125  3 mm) column (Macherey-Nagel GmbH) was used as stationary phase with 
water/acetonitrile mixtures as eluent. All solvents were HPLC grade. Reagents were used as 
obtained from commercial suppliers without further purification. Flash chromatography was 
performed on silica gel 60, 70-230 mesh (Fluka) and the reaction progress was determined by 
thin-layer chromatography (TLC) analyses on silica gel 60, F254 (Merck). Visualization was 
accomplished with UV light and staining with basic potassium permanganate (KMnO4). The 
melting points were measured using melting point apparatus SMP3 (Stuart Scientific). The 
apparatus is uncorrected. 
The following compounds were prepared according to previously described procedures: HHQ, 
PQS, 1 and 7.
[1] 
 
Synthesis of Title Compounds 
 
2-Heptyl-3-hydroxy-6-nitroquinolin-4(1H)-one (compound 2). 
A solution of 4 (200 mg, 0.63 mmol, 1.0 equiv) in dry THF (50 mL) was added dropwise to pure 
activated MnO2 (540 mg, 6.21 mmol, 9.9 equiv) at room temperature. The mixture was then stirred 
overnight. After filtration through Celite the solvent was removed under reduced pressure and the 
residue was purified by column chromatography on silica gel (dichloromethane:methanol, 80:1 v/v) 
to give 2-heptyl-6-nitro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde as a yellow solid (80 mg, 0.25 
mmol), which was unstable and used immediately in the next step. Boric acid (80 mg, 1.30 mmol, 
5.0 equiv) was suspended in THF (20 mL), followed by the addition of 30% H2O2 (90 µL, 3.0 
equiv) and conc. H2SO4 (0.5 mL). After stirring for 30 min a solution of the aldehyde (80 mg, 0.25 
mmol) in THF (10 mL) was added dropwise over 10 min. After additional stirring for 5 h, the 
mixture was filtered. The filtrate was neutralized by addition of a sat. NaHCO3 solution (120 mL) 
and the aqueous layer was extracted with ethyl acetate (3 x 30 mL). After drying of the combined 
–67– 
organic layers over MgSO4 the solvent was removed under reduced pressure. The residue was 
purified by preparative thin layer chromatography on silica gel (dichloromethane:methanol, 30:1 
v/v) to give 2 as a yellow solid (60 mg, 0.20 mmol, 32% for 2 steps). mp: 217.1-219.7 °C; 
1
H-NMR 
(500 MHz, DMSO-d6): δ 0.85 (t, J = 7.0 Hz, 3H), 1.24-1.39 (m, 8H), 1.67 (quint, J = 7.5 Hz, 2H), 
2.74 (t, J = 7.5 Hz, 2H), 7.70 (d, J = 9.0 Hz, 1H), 8.29 (dd, J = 2.5, 9.0 Hz, 1H), 8.71 (br, 1H), 8.90 
(d, J = 2.5 Hz, 1H), 11.99 (br, 1H); 
13
C-NMR (125 MHz, DMSO-d6): δ 13.9, 22.0, 27.6, 28.0, 28.4, 
28.7, 31.1, 119.5, 121.1, 121.8, 123.8, 136.8, 139.2, 140.2, 141.4, 169.2; LC/MS: m/z 305.03 [M + 
H]
+
, 99.9%.
[1]
 
2-Heptyl-6-nitro-4-oxo-1, 4-dihydroquinoline-3-carboxamide (compound 3). 
N,N’-Carbonyldiimidazole (62 mg, 0.38 mmol, 2.0 equiv) was added to 5 (62 mg, 0.19 mmol, 1.0 
equiv) in dry DMF (1 mL). After stirring at 65 °C for 5 h, the mixture was cooled to 0 °C and iced 
conc. NH3•H2O (5 mL) was added. After stirring overnight at room temperature the solvent was 
evaporated under reduced pressure. To the residue was added iced water (5 mL) and the pricipitate 
was isolated by filtration. After purification by column chromatography on silica gel 
(dichloromethane:methanol, 70:1 v/v) 3 was isolated as a white solid (43 mg, 0.13 mmol, 68%), 
mp: 237.6-239.1 °C; 
1
H-NMR (500 MHz, DMSO-d6): δ 0.86 (t, J = 7.0 Hz, 3H), 1.23-1.39 (m, 8H), 
1.69 (quint, J = 7.5 Hz, 2H), 3.00 (t, J = 8.0 Hz, 2H), 7.36 (br, 1H), 7.76 (d, J = 9.0 Hz, 1H), 8.45 
(dd, J = 2.5, 9.0 Hz, 1H), 8.54 (br, 1H), 8.86 (d, J = 2.5 Hz, 1H), 12.30 (br, 1H); 
13
C-NMR (125 
MHz, DMSO-d6): δ 13.9, 22.0, 28.3, 29.0, 29.2, 31.1, 32.7, 115.3, 119.9, 121.9, 123.9, 126.4, 142.4, 
143.1, 157.7, 166.7, 175.0; LC/MS: m/z 332.92 [M + H]
+
, 96.8%.
[2]
 
2-Heptyl-3-(hydroxymethyl)-6-nitroquinolin-4(1H)-one (compound 4). 
At 0 °C LiAlH4 (90 mg, 2.37 mmol, 2.0 equiv) was added to a stirred solution of 6 (420 mg, 1.17 
mmol, 1.0 equiv) in dry THF (20 mL). After stirring at room temperature for 2 h water (8 drops) 
and NaOH (2 drops, 15%) were added at 0 °C and after filtration the solvent was removed under 
reduced pressure. The residue was purified by column chromatography (dichloromethane:methanol, 
60:1 v/v) and washed with n-hexane to give 4 as a yellow solid (35 mg, 0.11 mmol, 9%), mp: 
>350 °C; 
1
H-NMR (500 MHz, DMSO-d6): δ 0.86 (t, J = 7.0 Hz, 3H), 1.23-1.42 (m, 8H), 1.70 (quint, 
J = 7.5 Hz, 2H), 2.77 (t, J = 7.5 Hz, 2H), 4.48 (d, J = 5.5 Hz, 2H), 4.68 (t, J = 5.5 Hz, 1H), 7.70 (d, 
J = 9.0 Hz, 1H), 8.39 (dd, J = 2.5, 9.0 Hz, 1H), 8.84 (d, J = 3.0 Hz, 1H), 11.93 (br, 1H); 
13
C-NMR 
(125 MHz, DMSO-d6): δ 13.9, 22.0, 28.4, 29.0, 29.2, 31.1, 53.4, 119.6, 119.9, 121.9, 122.9, 125.6, 
142.3, 143.2, 153.9, 175.6; LC/MS: m/z 319.06 [M + H]
+
, 99.9%.
[3]
 
2-Heptyl-6-nitro-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (compound 5). 
6 (250 mg, 0.69 mmol) was suspended in 10% NaOH (50 mL) solution and heated at reflux for 4 h. 
After cooling to 0 °C on an ice water bath and extraction with ethyl acetate, the water phase was 
acidified with conc. HCl to reach a pH of 4.0-6.0. 5 was isolated by filtration, washed with water 
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and dried under vacuum as a gray solid (32 mg, 0.10 mmol, 14%). mp: 192.7-194.9 °C; 
1
H-NMR 
(500 MHz, DMSO-d6): δ 0.86 (t, J = 7.0 Hz, 3H), 1.27-1.44 (m, 8H), 1.67 (quint, J = 7.5 Hz, 2H), 
3.26 (t, J = 7.5 Hz, 2H), 7.91 (d, J = 9.0 Hz, 1H), 8.58 (dd, J = 2.5, 9.0 Hz, 1H), 8.90 (d, J = 2.5 Hz, 
1H), 13.22 (br, 1H), 15.64 (br, 1H); 
13
C-NMR (125 MHz, DMSO-d6): δ 13.9, 22.0, 28.3, 29.1, 31.1, 
33.3, 107.6, 120.8, 121.5, 122.7, 127.7, 141.6, 144.2, 163.9, 165.4, 178.6; LC/MS: m/z 332.90 [M + 
H]
+
, 98.8%. 
Ethyl 2-heptyl-6-nitro-4-oxo-1, 4-dihydroquinoline-3-carboxylate (compound 6). 
Under nitrogen atmosphere 7 (3.40 g, 15 mmol, 1.0 equiv) was added to a suspension of sodium 
hydride (50-65% w/w, 0.75 g, 15 mmol, 1.0 equiv) in dry DMF (50 mL), causing the liberation of 
hydrogen gas. A solution of 6-nitro-1H-benzo[d][1,3]oxazine-2,4-dione (3.0 g, 14 mmol, 0.9 equiv) 
in dry DMF (30 mL) was added dropwise and stirred overnight. Most of the solvent was removed 
under reduced pressure and the remaining solvent treated with 1M HCl, yielding the crude product 
as a yellow solid. After recrystallization from ethyl acetate/methanol 6 was isolated as a yellow 
solid (1.8 g, 5.71 mmol, 41%). mp: 239.6-241.8 °C; 
1
H-NMR (500 MHz, MeOH-d4): δ 0.91 (t, J = 
7.0 Hz, 3H), 1.29-1.47 (m, 11H), 1.78 (quint, J = 7.5 Hz, 2H), 2.80 (t, J = 8.0 Hz, 2H), 4.39 (q, J = 
8.0 Hz, 2H), 7.72 (d, J = 9.0 Hz, 1H), 8.49 (dd, J = 2.5, 9.0 Hz, 1H), 9.04 (d, J = 2.5 Hz, 1H); 
13
C-NMR (125 MHz, MeOH-d4): δ 14.4, 14.6, 23.3, 30.3, 30.5, 30.6, 32.8, 33.8, 62.6, 117.6, 120.8, 
123.1, 125.4, 127.8, 144.3, 145.4, 156.8, 167.8, 176.4. LC/MS; m/z 360.77 [M + H]
+
, 96.3%.
[4]
 
 
General Experimental Information-Biology 
 
Chemicals, Bacterial Strains, and Media 
Yeast extract was purchased from Fluka (Neu-Ulm, Germany), peptone from casein from Merck 
(Darmstadt, Germany), Bacto™ Tryptone from BD Biosciences (Heidelberg, Germany), and 
Gibco
®
 phosphate-buffered saline (PBS) from Life Technologies (Darmstadt, Germany). Salts and 
organic solvents of analytical grade were obtained from VWR (Darmstadt, Germany). 
P. aeruginosa strain PA14 (PA14), the isogenic pqsH and pqsA transposon mutants, and the 
isogenic pqsR knockout mutant were stored in glycerol stocks at - 80 °C. 
The following media were used: Luria Bertani broth (LB), PPGAS medium,
[5]
 and modified M9 
minimal medium (20 mM NH4Cl; 12 mM Na2HPO4; 22 mM KH2PO4; 8.6 mM NaCl; 1 mM, 
MgSO4; 1 mM CaCl2; 11 mM glucose).
[6]
 
 
Reporter Gene Assay in E. coli 
The ability of the compounds to either stimulate or antagonize the PqsR-dependent transcription 
was analysed as previously described
[1]
 using a β-galactosidase reporter gene assay in E. coli 
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expressing PqsR. Briefly, a culture of E. coli DH5α cells containing the plasmid pEAL08-2, which 
encodes PqsR under the control of the tac promoter and the β-galactosidase reporter gene lacZ 
controlled by the pqsA promoter, were co incubated with test compound. Antagonistic effects of 
compounds were assayed in the presence of 50 nM PQS. After incubation, β- galactosidase activity 
was measured spectralphotometrically at OD420nm using POLARstar Omega (BMG Labtech, 
Ortenberg, Germany) and expressed as percent stimulation of controls. For the determination of 
IC50 values, compounds were tested at least at eight different concentrations. The given data 
represent mean values of two experiments with n = 4. 
 
Reporter Gene Assay in P. aeruginosa 
In order to study the antagonistic and agonistic properties of compounds 1, 2 and 3 in P. aeruginosa, 
the PqsR-dependent transcription was evaluated using a β-galactosidase reporter gene assay system. 
A PA14 strain carrying a non-functional pqsA gene to eliminate intracellular HHQ and PQS 
production was transformed with the plasmid pEAL08-2 and incubated with test compound in the 
presence or absence of 50 nM PQS and proceeded analogously to reporter gene assay in E. coli.  
 
Measurement of Compound 2 Levels 
In order to strengthen the theory of a possible biotransformation of the antagonistic compound 1 
levels of compound 2 produced by P. aeruginosa were investigated for PA14, pqsA and pqsH 
mutants. Cultures were inoculated with a starting OD600 = 0.1 in 100 mL Erlenmeyer flasks 
containing 50 mL LB medium. DMSO as a control or a DMSO solution of 1 (5 µM) was added to 
the cultures to a final DMSO concentration of 0.5%. The flasks were incubated at 37 °C, 200 rpm 
for 16 h. Every 60 min, samples of 995 µL of each culture were taken and supplemented with 15 µL 
of methanol containing 50 µM of the internal standard (HHQ-d4). The cells were lysed via 
sonification (amplitude 80%, 1 min) and compound 2 was extracted with 995 µL of ethyl acetate for 
1 min. After centrifugation (42,000 g, 2 min) 800 µL of the organic phase were transferred to a 
glass vial for vacuum evaporation. The residues were redissolved in 200 µL of methanol and 
subjected to UHPLC-MS/MS analysis. For each sample, cultivation and extraction were performed 
in triplicates.  
 
UHPLC-MS/MS Analysis of Extracted Compound 2 Levels 
UHPLC-MS/MS analysis was carried out on a TSQ Quantum Access Max mass spectrometer 
equipped with an HESI-II source and a triple quadrupole mass detector (Thermo Scientific, 
Dreieich, Germany). For analysis of compound 2, the following chromatographic conditions were 
used: 0.00-1.20 min, solvent gradient from 60% A up to 99% A, 1.21-1.80 min, isocratic 99% A, 
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1.81-2.00 min 60% A. Monitored ions were (mother ion [m/z], product ion [m/z], scan time [s], 
scan width [m/z], collision energy [V], tube lens offset [V], polarity): compound 2: 303.088, 
217.959, 0.2, 0.010, 32, 114, negative; internal standard (HHQ-d4): 248.340, 163.360, 0.2, 0.010, 32, 
113, positive. Samples were injected with a volume of 25 µL. The mobile phase consisted of 
acetonitrile containing 1‰ TFA (v/v; A) and 10 mM ammonium acetate buffer containing 1‰ TFA 
(v/v; B) and a flow rate of 0.8 mL/min. Xcalibur software was used for data acquisition and 
quantification using a calibration curve relative to the area of the IS. 
 
Determination of Extracellular HHQ and PQS Levels 
For determination of extracellular levels of HHQ and PQS produced by PA14, cultivation was 
performed in the following way: cultures (initial OD600 = 0.02) were incubated with or without 
inhibitor (final DMSO concentration 1%, v/v) at 37 °C, 200 rpm and a humidity of 75% for 16 h in 
24-well Greiner Bio-One (Frickenhausen, Germany) Cellstar plates containing 1.5 mL of LB 
medium per well. For HHQ analysis, according to the method of Lepine et al.,
[7]
 500 µL of the 
cultures supplemented with 50 µL of a 10 µM methanolic solution of the internal standard (IS) 
5,6,7,8-tetradeutero-2-heptyl-4(1H)-quinolone (HHQ-d4) were extracted with 1 mL of ethyl acetate. 
After centrifugation (18,620 g, 12 min), 400 µL of the organic phase were evaporated to dryness 
and redissolved in methanol. UHPLC-MS/MS analysis was carried out as described in detail by 
Storz et al..
[8]
 The monitored ions were (mother ion [m/z], product ion [m/z], scan time [s], scan 
width [m/z], collision energy [V], tube lens offset [V]): HHQ: 244, 159, 0.5, 0.01, 30, 106; HHQ-d4 
(IS): 248, 163, 0.1, 0.01, 32, 113. Quantification of PQS produced by PA14 was performed 
according to the method of Maurer et al.
[9]
 For each sample, cultivation and sample work-up were 
performed in triplicates. Inhibition values of HHQ and PQS formation were normalized to OD600. 
 
Pyocyanin Assay 
For analysis of pyocyanin formation, cultivation procedure was the same as for HHQ determination 
with the exception of using PPGAS medium. Pyocyanin produced by PA14 was quantified using 
the method of Essar et al.
[10]
 with some modifications, as described in detail by Klein et al..
[11]
 
Briefly, 900 μL of each culture were extracted with 900 μL of chloroform and 800 μL of the 
organic phase re-extracted with 250 μL of 0.2 M HCl. OD520 was measured in the aqueous phase 
using FLUOstar Omega (BMG Labtech, Ortenberg, Germany). For each sample, cultivation and 
sample work-up were performed in triplicates. Inhibition values of HHQ and PQS formation were 
normalized to OD600. 
 
Determination of Growth Curves of PA14 in Minimal Medium 
–71– 
Cultures of PA14 adjusted to a starting OD600 of 0.05 were grown in triplicates in 100 mL 
Erlenmeyer flasks containing 10 mL modified M9 minimal medium at 37 °C, 200 rpm and a 
humidity of 75%. DMSO alone or 15 µM DMSO solutions of compound 3 were added to the 
cultures to a final DMSO concentration of 1% (v/v). Bacterial growth was measured as a function of 
OD600 using Thermo Spectronic Helios Epsilon UV-VIS Spectrophotometer (Thermo Scientific, 
Dreieich, Germany). 
 
Caenorhabditis elegans Fast Killing Assay 
C. elegans nematodes (Bristol N2, wild type, German Center for Neurodegenerative Diseases, Bonn, 
Germany) were synchronized at fourth larval stage (L4) according to the protocol of Worm Book 
(www.wormbook.org). PA14 was incubated overnight in LB medium in the presence or absence of 
15 µM antagonist 3 containing 1% DMSO. After spreading of 10 µL of an overnight bacterial 
culture, the PGS plates with or without 15 µM antagonist 3 containing 1% DMSO were incubated at 
37 °C for 24 h and placed at room temperature for further 16 h. After transfer of 15-20 L4 C. 
elegans onto each plate, the mortality was scored every hour.
[12]
 The nematodes were considered 
dead or alive based on movements elicited by touching their heads gently with a thin wire or 
shaking the plates. For each condition, data from three independent experiments were combined. 
 
Galleria mellonella Virulence Assay 
G. mellonella larvae were purchased from local supplier (Angelsport Becker, Saarbrücken, 
Germany). For infection of the larvae, bacterial cultures were grown to exponential growth phase, 
adjusted to an OD600 of 1.6 in sterile PBS (pH 7.2), and serially diluted in PBS to obtain a lethal cell 
density (7 ± 1 CFUs/20 µL). CFUs were determined according to the method of Miles and Misra.
[13]
 
Aliquots of 5 µL were injected into the Galleria mellonella larvae (average weight 450 ± 50 mg) 
via the hindmost left proleg using a 10 µL Hamilton syringe. Larvae were incubated in Petri-dishes 
in the dark at 37 °C. Survival rates were monitored in time intervals of 12 h for 108 h post infection. 
Larvae were considered dead when no movement was observed in response to touch or when 
melanization of the cuticle occurred.
[14]
 Groups of 15 larvae each were subjected to the following 
treatments: injection of a) PA14 suspension diluted as described above, b) 10 pmol of compound 3 
dissolved in a), c) 5 pmol of compound 3 dissolved in a), d) PA14 isogenic pqsA transposon mutant 
suspension diluted as mentioned above, and e) PA14 isogenic pqsR knockout mutant suspension 
prepared as described above. For each treatment, data from at least two independent experiments 
were combined. 
 
Statistical Analysis 
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For the animal experiments, statistical analysis was performed using GraphPad Prism 5.04 software. 
Survival curves were generated by the Kaplan-Meier method and analyzed by the log-rank 
(Mantel-Cox) test. IC50 values were calculated with Origin 8 software. 
 
Supplementary Results 
 
 
Figure S1. Chromatograms of SRM transition m/z 303>218 indicating biotransformation 
product (upper diagram) and chemically synthesized reference 2 (lower diagram). 
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Figure S2. Production of compound 2 in PA14, pqsA and pqsH mutants after 16 hours. Strains 
were incubated with 1 at 5 µM. 
 
 
Figure S3. Competition experiment with PqsR antagonist 1 and agonist 2 in E. coli 
β-galactosidase reporter gene assay. The assay was performed in the presence of 50 nM PQS. For 
Y axis, 0% is defined as the basal PqsR stimulation without ligands and 100% is defined as the 
PqsR stimulation by 50 nM PQS. 
 
 
Figure S4. Synthetic route of compounds 2 and 3. Reagents and conditions: a) NaH, dry DMF, r.t. 
then HCl; b) NaOH, H2O, reflux then HCl; c) N,N’-carbonyldiimidazole, NH3•H2O, dry DMF, 0 °C 
– r.t.; d) LiAlH4, dry THF, 0 °C – r.t.; e) MnO2, dry THF, r.t. then B(OH)3, conc. H2SO4, H2O2, 
THF, r.t. 
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Figure S5. Growth curves of PA14 in modified M9 minimal medium in the absence (control) 
and presence of 15 µM of compound 3. 
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